Introduction
============

Donepezil is the number one member of the second generation of acetylcholinesterase inhibitors (AChEIs) (ie, donepezil, rivastigmine, galantamine) ([Table 1](#t1-ndt-3-303){ref-type="table"}) developed for the treatment of Alzheimer's disease (AD) after the postulation in the early 1980s that AD was associated with a central cholinergic deficit ([@b14-ndt-3-303]; [@b242-ndt-3-303]). The first generation of AChEIs was represented by physostigmine, tacrine, velnacrine, and metrifonate of which only tacrine reached the marked in 1993 with an ephemeral life due to pharmacokinetic and pharmacodynamic problems ([@b95-ndt-3-303]). After the closure of tacrine production, donepezil became the mainstay of AD therapeutics from 1996 up to now. More than 1000 papers have been published on the properties of donepezil during the past decade (1996--2006). About 800 papers deal with donepezil in dementia (\>300 clinical trials worldwide) ([Table 2](#t2-ndt-3-303){ref-type="table"}), and approximately 100 papers refer to the role of donepezil in other central nervous system (CNS) disorders. At the present time, donepezil is the leading compound for AD treatment in the world (marketed in 56 countries) ([@b214-ndt-3-303]).

Major issues for a drug to be successful include efficacy, safety, and at least some pharmacoeconomic benefit. On average, most studies with AChEIs reported by the pharmaceutical industry showed a cognitive enhancement of 2--3 points (vs placebo) in the ADAS-Cog score in clinical trials of 12--30 weeks' duration, with improvement in 12%--58% of patients, 5%--73% of drop-outs, and side-effects in 2%--58% of cases ([@b95-ndt-3-303]). As compared with other AChEIs, donepezil exhibits the best pharmacological profile in terms of cognitive improvement (2.8--4.6 vs 0.7--1 points of difference with placebo in the ADAS-Cog scale), responders rate (40%--58%), drop-out cases (5%--13%), and side-effects (6%--13%) ([@b95-ndt-3-303]). Most studies agree that donepezil is a safe drug, although important adverse drug reactions (ADRs) have been reported in the international literature ([Table 3](#t3-ndt-3-303){ref-type="table"}). However, when evaluating efficacy and safety issues with AChEIs in AD, methological limitations in some studies reduce the confidence of independent evaluators in the validity of the conclusions drawn in published reports ([@b62-ndt-3-303]; [@b132-ndt-3-303]; [@b108-ndt-3-303]; [@b119-ndt-3-303]; [@b137-ndt-3-303]). For pharmacoeconomic aspects, some studies assessing the cost-effectiveness of ChEIs suggest that AChEI therapy provides benefit at every stage of disease, with better outcomes resulting from persistent, uninterrupted treatment ([@b83-ndt-3-303]; [@b198-ndt-3-303]; [@b81-ndt-3-303]), whereas other studies indicate that AChEIs are not cost-effective, with benefits below minimally relevant thresholds or cost-neutral ([@b62-ndt-3-303]; [@b246-ndt-3-303]; [@b247-ndt-3-303]; [@b137-ndt-3-303]). The average annual cost per person with dementia ranges from US\$15,000 to US\$50,000, depending upon disease stage and country, with a lifetime cost per patient of more than US\$175,000. Approximately, 80% of the global costs of dementia (direct and indirect costs) are assumed by the patients and/or their families, and 10%--20% of the costs of dementia are attributed to pharmacological treatment ([@b44-ndt-3-303], [@b45-ndt-3-303]). Considering an average survival time (from diagnosis to death) of 10 years in optimal conditions, receiving 4--6 different drugs/day, a patient with dementia expends about US\$4500--6000 per year (≈US\$50,000 in a decade) in medicines.

Since the past experience in AD therapeutics was regrettably unsuccessful, donepezil is a good paradigm to interpret the past and to plan ahead future pharmacological challenges in order to optimize the treatment of dementia, incorporating novel data about the impact of pharmacogenetics on AD therapeutics and the influence of genetic factors on efficacy and safety issues.

Molecular pathology of Alzheimer's disease
==========================================

AD is a polygenic/multifactorial complex disorder characterized by the premature death of neurons. More than 200 different genes distributed across the human genome have been potentially involved in the pathogenesis of AD ([@b52-ndt-3-303]). The genetic defects identified in AD during the past 25 years can be classified into 3 main categories: (a) Mendelian or mutational defects in genes directly linked to AD, including (i) 18 mutations in the amyloid beta (Aβ) precursor protein (APP) gene (21q21); (ii) 142 mutations in the presenilin 1 (PS1) gene (14q24.3); and (iii) 10 mutations in the presenilin 2 (PS2) gene (1q31--q42). (b) Multiple polymorphic variants of risk characterized in more than 200 different genes distributed across the human genome can increase neuronal vulnerability to premature death ([@b52-ndt-3-303]). Among these genes of susceptibility, the apolipoprotein E (APOE) gene (19q13.2) is the most prevalent as a risk factor for AD, especially in those subjects harbouring the APOE-4 allele, whereas carriers of the APOE-2 allele might be protected against dementia. APOE-related pathogenic mechanisms are also associated with brain aging and with the neuropathological hallmarks of AD. (c) Diverse mutations located in mitochondrial DNA (mtDNA) through heteroplasmic transmission can influence aging and oxidative stress conditions, conferring phenotypic heterogeneity. It is also likely that defective functions of genes associated with longevity may influence premature neuronal survival, since neurons are potential pacemakers defining life span in mammals. All these factors may interact in as yet unknown genetic networks leading to a cascade of pathogenic events characterized by abnormal protein processing and misfolding with subsequent accumulation of abnormal proteins (conformational changes), ubiquitin-proteasome system dysfunction, excitotoxic reactions, oxidative and nitrosative stress, mitochondrial injury, synaptic failure, altered metal homeostasis, dysfunction of axonal and dendritic transport and chaperone misoperation ([@b32-ndt-3-303]; [@b44-ndt-3-303], [@b45-ndt-3-303]; [@b52-ndt-3-303]). Some of these mechanisms are common to several neurodegenerative disorders which differ depending upon the gene(s) affected and the involvement of specific genetic networks, together with cerebrovascular factors, epigenetic factors, oxidative stress phenomena, and environmental conditions (eg, nutrition, toxicity, social factors) ([@b32-ndt-3-303]; [@b52-ndt-3-303]; Mattson and Magnus 2006). The higher the number of defective genes involved in AD pathogenesis, the earlier the onset of the disease, the faster its clinical course and the poorer its therapeutic outcome ([@b44-ndt-3-303], [@b45-ndt-3-303]; [@b52-ndt-3-303]).

Although the amyloid hypothesis is recognized as the *primum movens* of AD pathogenesis ([@b201-ndt-3-303]; [@b215-ndt-3-303]; [@b52-ndt-3-303]), mutational genetics associated with amyloid precursor protein (APP) and presenilin (PS) genes alone (\<10% of AD cases) does not explain in full the neuropathologic findings present in AD, represented by amyloid deposition in senile plaques and vessels (amyloid angiopathy), neurofibrillary tangle (NFT) formation due to hyperphosphorylation of tau protein, synaptic and dendritic desarborization and neuronal loss ([@b99-ndt-3-303]). These findings are accompanied by neuroinflammatory reactions, oxidative stress, and free radical formation probably associated with mitochondrial dysfunction, excitotoxic reactions, alterations in cholesterol metabolism and lipid rafts, deficiencies in neurotransmitters (especially acetylcholine) and neurotrophic factor function, defective activity of the ubiquitin-proteasome, and chaperone systems and cerebrovascular dysregulation ([@b52-ndt-3-303]). All these neurochemical events are potential targets for treatment; however, it is very unlikely that a single drug be able alone to neutralize the complex mechanisms involved in neurodegeneration ([@b44-ndt-3-303], [@b45-ndt-3-303]; [@b52-ndt-3-303]; [@b58-ndt-3-303]).

The cholinergic hypothesis
==========================

Before the understanding of the complex pathology of AD, in the late 1970s and early 1980s it was believed that AD-related memory dysfunction was in part due to a cholinergic deficit in the brain of affected people due to a loss of neurons in the basal forebrain, this giving rise to the cholinergic hypothesis of AD ([@b14-ndt-3-303]; [@b242-ndt-3-303]; [@b86-ndt-3-303]). The role of acetylcholine on memory function had been postulated many years before, and it was reasonable to think that a cholinergic deficit associated with an age-related decline in the number of neurons (50%--87%) of the nucleus basalis of Meynert accompanied by a reduced number of cholinergic synapses in cortical fronto-parietal-temporal regions and in the entorhinal cortex, might justify the memory deficit present in AD patients ([@b14-ndt-3-303]). From the 1950s to the 1980s "the amyloid hypothesis" and "the tau hypothesis" were elaborated, and both theories became the dominant and confronted pathogenic mechanisms potentially underlying AD-related neurodegeneration ([@b99-ndt-3-303]). However, recent genomic studies suggest that amyloid deposition in senile plaques, NFT and cholinergic deficits are but the phenotypic expression of the disease, and that the causative mechanism of premature neuronal death should be upstream of all these pathogenic events ([@b52-ndt-3-303]).

Since choline donors (precursors) and acetylcholine itself were substances of difficult pharmacological management (or useless to increase brain cholinergic neurotransmission), and, paradoxically, considering that acetylcholinesterase activity progressively decreased in AD brains in parallel with cognitive deterioration, AChEIs were proposed as an option to inhibit acetylcholine degradation in the synaptic cleft and to increase choline reuptake at the presynaptic level with the aim of enhancing acetylcholine synthesis in presynaptic terminals, this facilitating cholinergic neurotransmission ([@b95-ndt-3-303]). The first candidate to fulfil this criteria was tacrine (tetrahydroaminoacridine) ([@b216-ndt-3-303]), which after its introduction in the market in 1993 soon fell out of favor due to its hepatotoxicity and poor tolerability; 3 years later, in 1996, donepezil was approved by the FDA for the treatment of mild-to-moderate cases of AD. The other AChEIs, rivastigmine and galantamine, were introduced several years later ([@b95-ndt-3-303]).

Pharmacological properties of donepezil
=======================================

Donepezil, 1-benzyl-4-\[(5,6-dimethoxy-1-indanon)-2-yl\]methylpiperidine hydrochloride (E2020), is an indanone benzylpiperidine derivative ([@b213-ndt-3-303]) with selective reversible AChEI activity in the CNS and other tissues ([@b161-ndt-3-303]; [@b96-ndt-3-303]; [@b214-ndt-3-303]). Donepezil is approximately 10 times more potent than tacrine as an inhibitor of acetylcholinesterase (AChE), and 500--1000-fold more selective for AChE over butyrylcholinesterase (BuChE). This compound is slowly absorbed from the gastrointestinal tract and has a terminal elimination half-life of 50--70 hours in young volunteers (\>100 hours in elderly subjects) ([@b166-ndt-3-303]). After extensive metabolization in the liver, the parent compound is 93% bound to plasma proteins ([@b106-ndt-3-303]).

AChEIs exhibit different affinities and selectivity for AChE and BuChE; however, most of them display a similar potency and clinical efficacy at conventional doses, this fact suggesting that these compounds may exert their therapeutic effects via collateral mechanisms unrelated to or indirectly linked with cholinesterase inhibition. Their chemical structures are also responsible for their pharmacokinetic and pharmacodynamic properties (Nordberg and Svensson 1999). For instance, physostigmine and rivastigmine are carbamates with pseudo-irreversible AChE-BuChE inhibition; tacrine is an acridine with reversible inhibition on the AChE-BuChE substrates; metrifonate is an organophosphate with irreversible inhibition of AChE-BuChE; donepezil is a piperidine with highly specific, reversible AChE inhibition; galantamine is a phenanthrene with reversible inhibition of AChE-BCh; and huperzine A is a pyridine with specific, reversible AChE inhibition ([@b95-ndt-3-303]) ([Table 1](#t1-ndt-3-303){ref-type="table"}). The order of inhibitory potency (IC50) towards AChE activity under optimal assay conditions for each AChEI is the following: physostigmine (0.67 nM) \> rivastigmine (4.4 nM) \> donepezil (6.7 nM) \> TAK-147 (12 nM) \> tacrine (77 nM) \> ipidacrine (270 nM). According to this study performed by Eisai scientists, the benzylpiperidine derivatives donepezil and TAK-147 showed high selectivity for AChE over BuChE; the carbamate derivatives showed moderate selectivity, while the 4-aminopyridine derivatives tacrine and ipidacrine showed no selectivity ([@b164-ndt-3-303]). More recent studies indicate that donepezil is 40--500-fold more potent than galantamine in inhibiting AChE. Clearance of galantamine from the brain is faster than donepezil. Ki values of brain AChE inhibition for galantamine and donepezil, respectively, are 7.1--19.1 and 0.65--2.3 μg/g in different species, suggesting that for a similar degree of brain AChE inhibition, 3--15 times higher galantamine than donepezil doses are needed ([@b92-ndt-3-303]).

The pharmacokinetic properties of AChEIs are also different. Tacrine, donepezil, and galantamine are metabolized in the liver via the cytochrome P450 system (CYP1A2-, CYP2D6-, CYP3A4-related enzymes), whereas rivastigmine is metabolized through carbomoylation ([Table 1](#t1-ndt-3-303){ref-type="table"}). Donepezil potentially may interact with drugs metabolized via CYP1A2-, CYP2D6-, and CYP3A4-related enzymes; however, formal pharmacokinetic studies have revealed no clinically meaningful interactions with memantine, risperidone, sertraline, carbidopa/levodopa, theophylline, furosemide, cimetidine, warfarin, and digoxin ([@b223-ndt-3-303], [@b224-ndt-3-303], [@b225-ndt-3-303], [@b226-ndt-3-303], [@b227-ndt-3-303], [@b228-ndt-3-303]; [@b202-ndt-3-303]). Their half-life also differ from 2--4 hours (tacrine, metrifonate, phenserine) to 4--6 hours (rivastigmine, galantamine), and 73 hours (donepezil). Bioavailability is maximum for galantamine (100%) and metrifonate (90%), both substances showing the lowest plasma protein binding (10--20%) in contrast to donepezil (96%) (Nordberg and Svensson 1999; [@b77-ndt-3-303]; [@b17-ndt-3-303]; Farmow 2003; [@b95-ndt-3-303]). In animals, donepezil is found unchanged in brain, and no metabolites are detected in the nervous tissue. In plasma, urine, and bile, most donepezil metabolites are O-glucuronides ([@b145-ndt-3-303]). In healthy volunteers, donepezil is hepatically metabolized and the predominant route for the elimination of both parent drug and its metabolites is renal, as 79% of the recovered dose was found in the urine with the remining 21% found in feces. Moreover, the parent compound is the predominant elimination product in urine. The major metabolites of donepezil include M1 and M2 (via O-dealkylation and hydroxylation), M11 and M12 (via glucuronidation of M1 and M2, respectively), M4 (via hydrolysis) and M6 (via N-oxidation) ([@b228-ndt-3-303]).

After 14 days administration of donepezil, the cerebral acetylcholine level is increased by 35% and the AChE activity is decreased by 66% and 32% in rat brain and blood, respectively. No changes are detected in choline acetyltransferase activity, or the levels of vesicular acetylcholine transporter, choline transporter, or muscarinic receptors. The expression of various cholinergic genes is not affected by donepezil. Donepezil increases acetylcholine concentration in the synaptic cleft of the hippocampus mostly through AChE inhibition ([@b128-ndt-3-303]) and produces a dose-dependent increase in hippocampal theta rhythm amplitude elicited by stimulation of the brainstem reticular formation ([@b124-ndt-3-303]). AChE activity in human blood shows 60%--97% and 43%--89% of pre-exposed level after 1 and 3 days of donepezil administration at a daily dose of 5 mg, respectively ([@b105-ndt-3-303]). The current doses of donepezil at the clinical setting are 5 and 10 mg/day. Above 10 mg, AChE inhibition is assumed to reach a plateau ([@b116-ndt-3-303]).

It is likely that the modest (and variable) therapeutic effects of AChEIs are related to their pharmacological properties and individual capacity to inhibit AChE activity in AD brains. [@b179-ndt-3-303] compared the effects of 8 AChEIs on AChE and BuChE activity in normal human brain cortex. The most selective AChEIs, in decreasing order were: TAK-147, donepezil, and galantamine. For BuChE, the most specific was rivastigmine; however, none of these AChEIs was absolutely specific for AChE or BuChE. Among these inhibitors, tacrine, bis-tacrine, TAK-147, metrifonate, and galantamine inhibited both the G1 and G4 AChE forms equally well ([@b179-ndt-3-303]).

The cognitive effects of AChEIs have been studied under different paradigms. The most frequent experiments have been performed in animals with cholinergic deficits or with lesions of the nucleus basalis of Meynert, as well as in animal models of AD and transgenic animals.

Donepezil can also act on targets other than cholinesterases in the brain. Among possible indirect actions of AChEIs to protect AD neurons, several options have been postulated. In dissociated hippocampal neurons, donepezil reversibly inhibits voltage-activated Na+ currents, and delays rectifier K+ current and fast transient K+ current. The inhibition of donepezil on rectifier K+ currents is voltage-dependent, whereas that on fast transient currents is voltage-independent. The blocking effects of donepezil on the voltage-gated ion channels are unlikely to contribute to its clinical effects in AD ([@b255-ndt-3-303]).

Donepezil up-regulates nicotinic receptors in cortical neurons, this probably contributing to enhance neuroprotection ([@b130-ndt-3-303]). It has also been suggested that AChEIs might promote non-amyloidogenic pathways of APP processing by stimulation of α-secretase mediated through protein kinase C (PKC) ([@b169-ndt-3-303]). In the transgenic Tg2576 mouse model of AD, which exhibits age-dependent β-amyloid deposition in the brain as well as abnormalities in the sleep-wakefulness cycle probably due to a cholinergic deficit, the wake-promoting efficacy of donepezil is lower in plaque-bearing Tg2576 mice than in controls ([@b251-ndt-3-303]). In AD cases, donepezil increases the percentage of REM (rapid eye movements) sleep to total sleep time, improving sleep efficiency and shortening sleep latency ([@b151-ndt-3-303]; [@b153-ndt-3-303]). In healthy volunteers, donepezil specifically enhances the duration of REM sleep (% sleep period time) and the number of REMs (Nissen et al 2005). The activation of the visual association cortex during REM sleep by donepezil might be responsible for the development of abnormal dreams and nightmares in AD ([@b206-ndt-3-303]).

The influence of AChEIs on APP processing and inhibition of β-amyloid formation, at least in the case of some AChEIs (eg, phenserine), does not appear to be associated with cholinesterase inhibition but with a novel mechanism regulating translation of APP mRNA by a putative interleukin-1 or TGF-β responsive element which has been proposed as a target for drug development ([@b204-ndt-3-303]). Donepezil and other AChE noncovalent inhibitors are able to inhibit AChE-induced β-amyloid aggregation ([@b231-ndt-3-303]). AChEIs may also protect against vascular damage and amyloid angiopathy. In mild--moderate AD patients, increased levels of markers of endothelial dysfunction, such as thrombomodulin and sE-selectin have been observed. After treatment with AChEIs for 1 month, the levels of both parameters are markedly reduced, with values approaching normal ranges ([@b29-ndt-3-303]). In the Tg2576-transgenic mouse model in which, at 9--10 months of age, Tg+ mice develop amyloid plaques and impairments on paradigms related to learning and memory as compared to transgene-negative (Tg−) mice, physostigmine and donepezil improve deficits in contextual and cued memory in Tg+, but neither drug alter the deposition of amyloid plaques ([@b68-ndt-3-303]). In contrast, donepezil protects against the neurotoxic effects induced by β-amyloid(1--40) in primary cultures of rat septal neurons ([@b123-ndt-3-303]). In another transgenic model of AD, the AD11 anti-nerve growth factor (anti-NGF) mice, oral administration of ganstigmine (CHF2819) and donepezil reverses the cholinergic and behavioral deficit in AD11 mice but not the amyloid and phosphotau accumulation, uncovering different mechanisms leading to neurodegeneration in AD11 mice ([@b60-ndt-3-303]).

Probably via cholinergic modulation at the hypothalamic level, donepezil is able to reverse the age-related down-regulation of the GH/IGF-1 axis in elderly males in basal conditions and after GHRH stimulation. GHRH-induced GH response is magnified by more than 50% after treatment with donepezil in healthy elderly subjects ([@b163-ndt-3-303]). The enhancement of the somatotropinergic sistem (GRF-GH-IGF axis) associated with donepezil treatment might contribute to activate GRF/GH-related neurotrophic mechanisms ([@b54-ndt-3-303], [@b55-ndt-3-303]). AChEIs also influence pro-inflammatory cytokines released from peripheral blood mononuclear cells, increasing oncostatin M, IL-1β, and IL-6 levels in AD patients after treatment ([@b183-ndt-3-303]).

Glutamate-related excitotoxicity is an additional deleterious mechanism secondarily contributing to AD neuropathology ([@b59-ndt-3-303]). The neuroprotective properties of AChEIs on glutamate-induced excitotoxicity were investigated in primary cultured cerebellar granule neurons. Exposure of neurons to glutamate results in neuronal apoptosis. In this model, bis(7)-tacrine, a novel dimeric AChEI markedly reduces glutamate-induced apoptosis in a time- and dose-dependent manner; however, donepezil and other conventional AChEIs do not show any effect ([@b134-ndt-3-303]). Donepezil blocks the responses of recombinant NMDA receptors expressed in *Xenopus oocytes*. The blockade is voltage-dependent, suggesting a channel blocker mechanism of action which is not competitive at either the L-glutamate or glycine binding sites. The low potency of donepezil indicates that NMDA receptor blockade does not contribute to its therapeutic effect in AD; however, donepezil binds to the sigma1 receptor with high affinity and shows antidepressant-like activity in the mouse forced-swimming test as does the sigma1 receptor agonist igmesine. All AChEIs attenuate dizocilpine-induced learning impairments, but only the donepezil and igmesine effects are blocked by BD1047 or the antisense treatment, suggesting that donepezil behaves as an effective sigma1 receptor agonist and that interaction with sigma1 protein, but not NMDA receptor, might be involved in the pharmacological activity of donepezil ([@b147-ndt-3-303]). Other studies indicate that donepezil has a neuroprotective effect against oxygene-glucose deprivation injury and glutamate toxicity in cultured cortical neurons, and that this neuroprotection may be partially mediated by inhibition of the increase of intracellular calcium concentration ([@b4-ndt-3-303]).

Donepezil influences cells viability and proliferation events in SH-SY5Y human neuroblastoma cells. Short- and long-exposure of these cells to donepezil induced a concentration-dependent inhibition of cell proliferation unrelated to muscarinic or nicotinic receptor blockade or apoptosis. Donepezil reduces the number of cells in the S-G2/M phases of the cell cycle, increases the G0/G1 population, and reduces the expression of two cyclins of the G1/S and G2/M transitions, cyclin E and cyclin B, in parallel with an increase in the expression of the cell cycle inhibitor p21 ([@b209-ndt-3-303]). Using the same in vitro model, others have reported that galantamine, donepezil, and rivastigmine afford neuroprotection through a mechanism that is likely unrelated to AChE inhibition, suggesting that at least donepezil and galantamine, but not rivastigmine, may exert their potential neuroproptective effects via α7 nicotinic receptors and the PI3K-Akt pathway ([@b9-ndt-3-303]). In addition, donepezil increases action potential-dependent dopamine release ([@b256-ndt-3-303]) and modulates nicotinic receptors of substantia nigra dopaminergic neurons ([@b66-ndt-3-303]).

Donepezil in Alzheimer's disease
================================

Most clinical trials with donepezil in AD during the past 10 years have been performed in patients with mild-to-moderate dementia (mAD) ([@b189-ndt-3-303], [@b190-ndt-3-303], [@b192-ndt-3-303]; [@b39-ndt-3-303]; [@b110-ndt-3-303]; [@b72-ndt-3-303], [@b71-ndt-3-303]; [@b152-ndt-3-303]; [@b248-ndt-3-303]) ([Table 2](#t2-ndt-3-303){ref-type="table"}), and a small number of studies have been carried out in severe cases of AD (sAD) ([@b79-ndt-3-303]; [@b38-ndt-3-303]; [@b249-ndt-3-303]) ([Table 2](#t2-ndt-3-303){ref-type="table"}). More than 10,000 patients recruited from 26 different countries have been included in major clinical trials with AChEIs (24--30 weeks' duration) during the past decade ([@b95-ndt-3-303]). The typical outcome measures in most trials include psychometric assessment, behavior and function with different scales. Although the differences in the design of clinical trials is obvious, in patients treated with donepezil the differences with placebo range from 0.7--1.2 to 2.8--4.6 points in the ADAS-Cog ([@b95-ndt-3-303]; [@b241-ndt-3-303]). Despite this optimistic view resulting from the observation of selected trials ([Table 2](#t2-ndt-3-303){ref-type="table"}), many other studies and meta-analyses (Glegg et al 2001; [@b132-ndt-3-303]; [@b119-ndt-3-303]; [@b137-ndt-3-303]; [@b22-ndt-3-303]; [@b22-ndt-3-303]) indicate that AChEIs in general and donepezil in particular are of poor efficacy in AD. In 16 trials with 5159 treated patients (placebo = 2795 patients) the pooled mean proportion of global responders to AChEIs in excess of that of placebo was 9%. The rate of adverse events, dropout for any reason and dropout because of adverse events were also higher among patients receiving AChEIs than among those receiving placebo, with an excess proportion of 7%--8% ([@b132-ndt-3-303]). In this meta-analysis, including 8 trials with donepezil, 2 trials with rivastigmine and 5 trials with galantamine, the cognitive response was positive in 23%--35% of patients treated with donepezil, in 30% of patients treated with rivastigmine, and in 20--32% of patients treated with galantamine. The dropout rate was 20%--60% due to adverse events ([@b132-ndt-3-303]). In a meta-analysis including 22 trials published from 1989 to 2004, 12 of 14 studies showed an improvement of 1.5--3.9 points in the ADAS-Cog; however, because of flawed methods and small clinical benefits, the German evaluators established that the scientific basis for recommendations of AChEIs in AD was questionable ([@b119-ndt-3-303]). In a 10-study meta-analysis of donepezil in AD and two-study combined analysis of donepezil in vascular dementia (VD), an Irish group concluded that although there are differences between AD and VD patients in comorbid conditions and concomitant medications, donepezil is effective and well tolerated in both types of dementia ([@b173-ndt-3-303]). In the AD2000 clinical trial of [@b63-ndt-3-303], no significant benefits were seen with donepezil compared with placebo in institutionalization or progression of disability. Similarly, no significant differences were seen between donepezil and placebo in behavioral and psychological symptoms, carer psychopathology, formal care costs, unpaid caregiver time, adverse events or deaths, or between 5 mg and 10 mg donepezil ([@b63-ndt-3-303]). In a critical appraisal of the AD2000 study, the first long-term RCT not sponsored by the pharmaceutical industry, a German group led by [@b120-ndt-3-303] concluded that the widespread use of AChEIs in AD is not supported by current evidence, and that long-term-randomized controlled trials focusing on patient-relevant outcomes instead of cognitive scores are urgently needed ([@b120-ndt-3-303]).

Recent studies in early-stage AD suggest significant treatment benefits of donepezil, supporting the initiation of therapy early in the disease course to improve daily cognitive functioning ([@b203-ndt-3-303]). During the past decade more than 100 papers dealt with the use of AChEIs or memantine in severe AD (sAD), but only a few studies provide evidence in favor of a positive therapeutic intervention with donepezil in sAD ([@b79-ndt-3-303], [@b80-ndt-3-303], [@b82-ndt-3-303]; [@b38-ndt-3-303]; [@b85-ndt-3-303]; [@b249-ndt-3-303]). In the international literature there are 13 articles related to donepezil in sAD, but only 3 fulfil strict criteria for further consideration ([@b182-ndt-3-303])

In one study, to evaluate efficacy and safety of donepezil in sAD, [@b79-ndt-3-303] found that donepezil had significant benefits over placebo on global, cognitive, functional, and behavioral measures in patients with sAD ([@b79-ndt-3-303], [@b82-ndt-3-303]). In another study of [@b80-ndt-3-303], donepezil demonstrated a significantly slower decline than placebo in instrumental and basic ADLs in patients with m/sAD. [@b38-ndt-3-303] found similar effects of donepezil and rivastigmine on cognition and behavior in m/sAD. [@b249-ndt-3-303] have studied 248 patients with severe AD (sAD) (MMSE score: 1--10) living in nursing homes of Sweden for 6 months. The patients (n = 128) received 5 mg/day of donepezil for 30 days and then 10 mg/day thereafter. The primary end points in this study were change from baseline to month 6 in the severe impairment battery (SIB) and modified Alzheimer's Disease Cooperative Study activities of daily living inventory for severe AD (ADCS-AD-severe). Under this protocol, 95 patients assigned donepezil and 99 patients assigned placebo (n = 120) completed the study. AD patients treated with donepezil improved more in SIB scores and declined less in ADCS-ADL-severe scores after 6 months of treatment compared with baseline than did the patients enrolled in the placebo group ([@b249-ndt-3-303]).

To evaluate the representation of frail older adults in randomized controlled trials (RCTs), and to assess consequences of under representation by analyzing drug discontinuation rates, [@b97-ndt-3-303] studied a cohort of older adults newly dispensed donepezil (n = 6424) in Ontario between September 2001 and March 2002, and compared patients dispensed donepezil to clinical trials subjects. In this interesting study, between 51% and 78% of the Ontario cohort would have been ineligible for RCT enrolment. Patients dispensed donepezil were older (\>80 years) and more likely to be in long-term care than RCT subjects. Overall, 27.8% of the Ontario cohort discontinued donepezil within 7 months of initial prescription, and the discontinuation rates were significantly higher for patients with a history of obstructive lung disease, active cardiovascular disease, or parkinsonism ([@b97-ndt-3-303]).

It would be highly recommendable that outcome measures of efficacy in the long-term incorporate specific AD-related biomarkers (eg, serum markers, cerebro-spinal fluid \[CSF\] markers, neuroimaging biomarkers \[MRI, fMRI, PET, SPECT\], brain atrophy rate, brain perfusion, optical topography) ([@b149-ndt-3-303]; [@b115-ndt-3-303]; [@b67-ndt-3-303]). In this regard, PET studies have demonstrated that donepezil-induced inhibition of cortical AChE is modest (19%--24%) in patients with mAD. In the brain of AD patients assessed with an AChE tracer by PET scanning, treatment with donepezil for 3 months reduced AChE activity by 39% in the frontal cortex, 29% in the temporal cortex, and 28% in the parietal cortex ([@b118-ndt-3-303]). The degree of cortical AChE inhibition correlates with changes in excutive and attentional functions ([@b27-ndt-3-303]). Long-term treatment with donepezil can lead to a lesser deterioration in qEEG, paralleling a milder neuropsychological decline ([@b187-ndt-3-303]), with reduction of slow-wave activity in frontal and temporo-parietal areas ([@b127-ndt-3-303]). Mean P300 ERPs are also improved in dementia after donepezil treatment ([@b239-ndt-3-303]). By using the rate of hippocampal atrophy as a surrogate marker of disease progression, [@b104-ndt-3-303] found that treatment with donepezil slows the progression of hippocampal atrophy in AD (mean annual rate of hippocampal volume loss: 3.82%) as compared with untreated patients (5.04%). Smaller hippocampal volume and inward variation of the lateral and inferomedial portions of the hippocampal surface were correlated with a poorer response to donepezil therapy in dementia ([@b65-ndt-3-303]). AD patients who show more severe cholinergic dysfunction and less severe structural damage of the hippocampus and parahippocampus are likely to respond to donepezil treatment ([@b218-ndt-3-303]). Atrophy of the substantia innominata was more pronounced in transiently and continuously responding groups than in non-responders. Logistic regression analysis revealed that the overall discrimination rate with the thickness of the substantia innominata was 70% between responders and non-responders, suggesting that atrophy of the substantia innominata on MRI helps to predict response to donepezil treatment in AD ([@b219-ndt-3-303]). [@b129-ndt-3-303] have found that donepezil treated patients had significantly smaller mean decreases in total and right hippocampal volumes and a smaller, nearly significant mean decrease in left hippocampal volume, compared with the placebo-treated patients. Other studies revealed that the diversity of clinical responses to donepezil therapy in AD is associated with regional cerebral blood flow (rCBF) changes, mainly in the frontal lobe ([@b205-ndt-3-303]). Furthermore, there is a parallelism between cognitive improvement and increase in brain M1 muscarinic receptor binding after treatment with donepezil in AD ([@b122-ndt-3-303]). AChE activity also decreases in the CSF of patients treated with donepezil, but changes in other biomarkers, such as BuChE activity, β-amyloid (1--42), tau and phosphorylated tau proteins are not affected by donepezil treatment ([@b171-ndt-3-303]).

In summary, it appears that donepezil is beneficial (in a dose-dependent manner) when assessed using global and cognitive outcome measures in AD; however, by finding the mean effect sizes of the treatment on the outcome measures of cognition from 8 empirical studies, it was determined that neither donepezil nor other AChEIs were greatly efficacious ([@b102-ndt-3-303]). Over 770 million days of patient use and an extensive publication database demonstrate that donepezil has a good tolerability and safety profile ([@b113-ndt-3-303]). The use of AChEIs in AD is currently appraised by the National Institute for Clinical Evidence (NICE). In a recent review providing the latest, best quality evidence of the effects of AChEIs on cognition, quality of life and adverse events in people with mild to moderately-severe AD (m/sAD), [@b217-ndt-3-303] stated (on a systemtic review of 26 RCTs) that AChEIs can delay cognitive impairment in m/sAD for at least 6 months duration; however, results from head to head comparisons are limited by the low number of studies and the study quality. The Cochrane Database Reviewers conclude that people with mAD or sAD treated for periods of 12, 24, or 52 weeks with donepezil experienced benefits in cognitive function, activities of the daily living and behavior. Study clinicians rated global clinical state more positively in treated patients, and measured less decline in measures of global disease severity ([@b23-ndt-3-303]). In general terms, there is not robust support for any AChEI because the treatment effects are small and are not always apparent in practice ([@b23-ndt-3-303]; [@b217-ndt-3-303]). Donepezil treatment may be associated with reduced mortality in nursing home residents with dementia ([@b88-ndt-3-303]) and with delayed nursing home placement ([@b93-ndt-3-303]), although some authors denied that donepezil was able to reduced the rate of institutionalization or disability in mAD ([@b63-ndt-3-303]; [@b211-ndt-3-303]). The meta-analysis of caregiver-specific outcomes in antidementia clinical trials revealed that AChEIs have a small beneficial effect on burden and active time use among caregivers of persons with AD ([@b135-ndt-3-303]).

Mild cognitive impairment
-------------------------

Mild cognitive impairment (MCI) is the postulated transitional state between the cognitive changes of normal aging and early AD ([@b174-ndt-3-303], [@b175-ndt-3-303]). The rate of progression to clinically diagnosable AD is 10%--15%/year among persons who meet the criteria for the amnestic form of MCI, in contrast to a rate of 1--2%/year among normal elderly persons ([@b174-ndt-3-303]). This is a clinical concept and instrumental aid invented to substitute the lack of accurate biological markers able to predict the risk of suffering AD. Despite its questionable value, it is important to keep in mind that neurodegeneration starts many years before the onset of the disease ([@b52-ndt-3-303]). It is very likely that AD neurons begin their deceasing process 20--40 years prior to the appearance of the first symptoms (eg, memory deficit, behavioral changes, functional decline, subtle praxis-related psychomotor alterations). In some patients with a specific genetic profile, it is possible to detect, by means of sensitive brain imaging techniques, a progressive brain dysfunction after the age of 30 years ([@b42-ndt-3-303], [@b45-ndt-3-303]). In this regard, it is clear that an early therapeutic intervention could be of some benefit for these patients precluding the possibility of a premature neuronal death or delaying the onset of the disease for several years. AChEIs have been proposed as feasible candidate drugs for the treatment of MCI ([@b212-ndt-3-303]; [@b196-ndt-3-303]; [@b89-ndt-3-303]).

Few studies have been performed with donepezil in MCI ([@b117-ndt-3-303]). In a double-blind, placebo-controlled, multicenter trial in US with 270 cases, a mild benefit in cognitive function has been reported ([@b195-ndt-3-303]). A Chinese group has performed a clinical trial with donepezil (2.5 mg/day for 3 months) in patients with amnestic MCI and found a significant improvement in cognitive performance as well as changes in the hippocampus as assessed by magnetic resonance spectroscopy (MRS) ([@b235-ndt-3-303]).

In a recent study, [@b175-ndt-3-303] evaluated 769 subjects with the amnestic subtype of MCI in a randomized, double-blind study with donepezil (10 mg/day) or vitamin E (2000 IU/day) for 3 years. The overall rate of progression from MCI to AD was 16%/year (212 patients evolved into the AD condition). As compared with the placebo group, there were no significant differences in the probability of progression to AD in the vitamin E group or the donepezil group during the 3 years of treatment. The donepezil group had a reduced likelihood of progression to AD during the first 12 months of the study, with better results among APOE-4 carriers ([@b175-ndt-3-303]).

The proposed benefit of AChEI therapy as a preventive strategy in MCI or as a regular option for people requesting some medication for memory improvement is far from clear and probably poses some underestimated dangers, despite the optimistic position of some authors ([@b117-ndt-3-303]). It has been observed that neuropsychological test performance deteriorates in healthy elderly volunteers receiving donepezil for 2 weeks; worsening is significant on tests of speed, attention, and short-term memory as compared with the placebo group, suggesting a perturbation of an already optimized cholinergic system in healthy subjects ([@b15-ndt-3-303]). If the rate of conversion form MCI into AD is about 10%--15% per year, it is probably irresponsible to sacrifice 80% MCI cases to pyrrhically protect only 10% assuming that AChEIs in healthy subjects may induce undesirable cognitive effects.

The postulated long-lasting effects of AChEIs for 1--5 years ([@b71-ndt-3-303]; [@b37-ndt-3-303]; [@b95-ndt-3-303]) were never clearly documented in well-controlled trials. In a recent study, [@b250-ndt-3-303] provide some support to the long-lasting efficacy and safety of donepezil after 3 years of treatment. In a cohort of 286 patients, there was a trend for patients receiving continuous therapy to have less global deterioration on the Gottfries-Brane-Steen scale than those who had delayed treatment. Small but statistically significant differences between the groups were observed for the secondary measures of cognitive function (MMSE scores) and cognitive and functional abilities (GDS) in favor of continuous donepezil therapy ([@b250-ndt-3-303]).

On a pathogenic basis, there is no evidence that AChEIs protect neurons against AD-related premature death. It might occur -- as demonstrated with multifactorial therapies in AD ([@b53-ndt-3-303]) -- that cognitive enhancement induced by AChEI administration is the result of forcing surviving neurons to overwork for a period of time after which neurons become exhausted with the subsequent acceleration of their metabolic decline. This phenomenon has been demonstrated after administration of a combination therapy with CDP-choline, piracetam, and metabolic supplementation ([@b53-ndt-3-303]). Under this therapeutic protocol, AD patients clearly improved for the first 9 months of treatment, and a progressive decline in therapeutic efficacy has been observed thereafter ([@b53-ndt-3-303]; [@b42-ndt-3-303], [@b44-ndt-3-303], [@b45-ndt-3-303]). The study of [@b175-ndt-3-303] might be a good paradigm to illustrate the same phenomenon with donepezil in MCI patients who showed a positive response during the first year of treatment and no effect after 3 years. Taking into account these observations, we should be very cautious with the administration of pharmaceuticals (as a preventive strategy) to patients with MCI until a clear long-lasting efficacy of the therapeutic options can be demonstrated. This is especially important when some studies reveal that chronic administration of AChEIs (eg, galantamine) may even increase mortality ([@b199-ndt-3-303]; [@b125-ndt-3-303]).

Combination therapies
---------------------

Combination drug therapy is the standard of care for treating many neuropsychiatric disorders and other medical conditions (eg, cardiovascular disease, hypertension, cancer, AIDS, diabetes). For the past 20 years, the pharmaceutical industry and the medical community have made a show of reluctance to treat AD with a combination therapy, but in fact most patients with dementia have been receiving an average of 6--9 different drugs per day in an attempt to control the multifaceted expressions of dementia. Multifactorial therapy, combining several types of drugs with potential neuroprotective effect on the CNS, has been tried in AD and other forms of dementia with promising results ([@b47-ndt-3-303], [@b48-ndt-3-303]; [@b40-ndt-3-303], [@b41-ndt-3-303]; [@b42-ndt-3-303]; [@b53-ndt-3-303]; [@b44-ndt-3-303], [@b45-ndt-3-303]; [@b58-ndt-3-303]). Donepezil has been given in combination with other substances to patients with AD. Probably the best evidence-based combination strategy is the addition of memantine to stable donepezil therapy in m/sAD ([@b221-ndt-3-303]; van Dyck et al 2006). This combination was found to benefit cognition, behavior, and activities of daily living. It appears that memantine in combination with donepezil is significantly better than donepezil alone in the management of behavioral symptoms ([@b221-ndt-3-303]; [@b252-ndt-3-303]; [@b70-ndt-3-303]). Combination therapy with donepezil and memantine in healthy subjects did not show any significant alteration in pharmacokinetic or pharmacodynamic parameters of both drugs, suggesting that donepezil and memantine may be safely and effectively used in combination ([@b172-ndt-3-303]). According to basic studies using the whole-cell patch-clamp technique with multipolar neurons, the combination of donepezil and memantine might be a contradiction since donepezil potentiates NMDA currents ([@b154-ndt-3-303]) and memantine acts as a partial NMDA antagonist ([@b59-ndt-3-303]).

Combination therapy of donepezil (5 mg/day) with ginkgo biloba (90 mg/day) for 30 days did not show any significant difference in cognitive performance, pharmacokinetics and pharmacodynamics of donepezil, indicating that ginkgo supplementation does not have major impact on donepezil therapy ([@b253-ndt-3-303]). Donepezil has also been given in combination with acetyl-L-carnitine (ALC) in AD. The addition of ALC to donepezil increased the response rate from 38% (AChEI alone) to 50% (AChEI + ALC) ([@b21-ndt-3-303]). Initial data resulting from combination studies of donepezil and vitamin E indicated that this long-term combination might be beneficial for AD ([@b126-ndt-3-303]).

Donepezil plus sertraline did not show any advantage over donepezil alone in AD, although the combination appeared to be beneficial in a subgroup of patients with moderate-to-severe behavioral and psychological symptoms ([@b84-ndt-3-303]). In patients with psychotic symptoms and lack of improvement of their delusions/hallucinations during perphenazine treatment, donepezil may reduce psychotic symptoms, suggesting that donepezil augmentation of neuroleptics (risperidone, olanzapine, quetiapine) may be appropriate for those patients for whom neuroleptic monotherapy either does not lead to symptom remission or is associated with intolerable side-effects ([@b18-ndt-3-303]). In some cases the combination of donepezil and neuroleptics may exacerbate extrapyramidal side-effects ([@b136-ndt-3-303]). In general, combination therapy tends to show better results than monotherapy with one AChEI or any other single drug for dementia ([@b40-ndt-3-303], [@b41-ndt-3-303]; [@b53-ndt-3-303]; [@b44-ndt-3-303], [@b45-ndt-3-303]). Similar results can be seen in animal models when donepezil is given in combination with other compounds ([@b208-ndt-3-303]).

Comparative studies
-------------------

Comparative studies with different AChEIs did not show any significant difference or traces of superiority among them in AD patients ([@b245-ndt-3-303]; [@b186-ndt-3-303]; [@b3-ndt-3-303]; [@b38-ndt-3-303]; [@b102-ndt-3-303]). In independent studies, there are apparent differences in ADAS-Cog changes, improvement rate, dropouts, and incidence of side-effects among different classes of AChEIs; however, since the clinical protocols vary from one study to another, these results are not comparable and unreliable. In a number of studies analysed by [@b95-ndt-3-303] comparing 7 AChEIs, the ADAS-Cog variation vs placebo (AD/P) was 4.0--5.3/0.8--2.8 with tacrine, 4.7/1.83 with eptastigmine, 2.8--4.6/0.7--1.2 with donepezil, 1.9--4.9/0.7--1.2 with rivastigmine, 2.8--3.2/0.5--0.75 with metrifonate, and 3.1--3.9/1.73 with galantamine. About 30%--50% of patients improved with tacrine, 40%--58% with donepezil, 25%--37% with rivastigmine, 35%--40% with metrifonate, and 10%--23% with galantamine. The drop-out rate was 55%--73% in patients treated with tacrine, 35% with eptastigmine, 5%--13% with donepezil, 15%--36% with rivastigmine, 2%--28% with metrifonate, and 10%--13% with galantamine. Side-effects were more prevalent in patients treated with tacrine (405--58%) than with the other AChEIs (donepezil, 6%--13%; rivastigmine, 15%--28%; metrifonate, 2%--12%; galantamine, 13%--16%) ([@b95-ndt-3-303]). In clinical terms, according to [@b22-ndt-3-303], despite the slight variations in the mechanism of action of donepezil, rivastigmine, and galantamine, there is no evidence of any substantial differences between them with respect to efficacy; even though there appears to be less adverse effects associated with donepezil compared with rivastigmine ([@b22-ndt-3-303]).

Effects on behavioral symptoms and functional deficits
------------------------------------------------------

Dementia is clinically characterized by memory disorders, behavioral changes, and progressive functional decline. The estimated prevalence of psychiatric symptoms in AD accounts for 40%--60% of the cases ([@b56-ndt-3-303]; [@b57-ndt-3-303]). In cross-sectional studies it has been reported that several psychiatric symptoms are associated with lower total MMSE scores and overall cognitive deterioration. Psychotic symptoms, especially delusions, hallucinations and misidentifications, are positively correlated with aggressive behavior and institutionalization. Agitation and wandering are also associated with rapid cognitive decline in dementia. In general, psychotic symptoms parallel an accelerated cognitive deterioration, partially induced by psychotropic drugs in some cases or by many other classes of drugs currently used by patients in geriatric long-term settings ([@b10-ndt-3-303]). In other cases, behavioral changes do not seem to be associated with exogenous factors and might be intrinsic to cortical atrophy and selective brain damage in dementia. The prevalence of psychotic symptoms in AD ranges from 15% to 50%, constituting a very common problem which is not always reduced by conventional anti-psychotic or antianxiety drugs. In addition, antypsychotics may increase the risk of cerebrovascular accidents and also contribute to cortical atrophy after years of chronic treatment ([@b56-ndt-3-303], [@b57-ndt-3-303]; [@b98-ndt-3-303]). Furthermore, behavioral symptoms in AD significantly increase direct costs of care (US\$10,670--16,141 higher annual costs in high-NPI as compared with low-NPI) ([@b155-ndt-3-303]). Several studies with AChEIs indicate that these compounds may exert a beneficial effect on some neuropsychiatric symptoms such as delusions, hallucinations, apathy, psychomotor agitation, depression and anxiety ([@b133-ndt-3-303]; [@b230-ndt-3-303]). It is likely that AChEIs interact with atypical neuroleptics to synergistically increase the antipsychotic effect, this allowing a potential reduction in the dose of neuroleptics ([@b238-ndt-3-303]). What has to be demonstrated is that this pharmacodynamic interaction is common to all AChEIs, because it can not be excluded that some AChEIs may also precipitate psychotic symptoms and exacerbate extrapyramidal side-effects when given in combination with neuroleptics (eg, donepezil + risperidone) ([@b136-ndt-3-303]).

Several papers have documented the parallel beneficial effects of donepezil on cognition and behavioral symptoms in AD ([@b146-ndt-3-303]; [@b220-ndt-3-303]; [@b170-ndt-3-303]; [@b90-ndt-3-303]; [@b91-ndt-3-303]; [@b109-ndt-3-303]) ([Table 2](#t2-ndt-3-303){ref-type="table"}). In clinical trials, sleep problems have been identified as side-effects of donepezil. Poor sleep quality can exacerbate behavioral problems among patients and add to the burden experienced by caregivers. In a community-based study, the use of hypnotics was higher in donepezil users (9.78%) compared with non-users (3.93%) ([@b210-ndt-3-303]). Behavioral symptoms are a major problem in AD and, assuming that most psychotropic drugs contribute to deteriorate cognition and psychomotor function, as well as cerebrovascular function ([@b140-ndt-3-303]; [@b98-ndt-3-303]), AChEIs represent an option to be explored in more detail as a monotherapy or in combination with other psychotropic agents at low doses ([@b13-ndt-3-303]; [@b143-ndt-3-303]).

Donepezil in vascular dementia
==============================

Cerebrovascular dysfunction is a common finding in dementia; and mixed dementia (MXD) (degenerative + vascular) is the most frequent form of dementia in older patients (\> 75--80 years) ([@b42-ndt-3-303]; [@b49-ndt-3-303], [@b50-ndt-3-303], [@b51-ndt-3-303]). Diverse vascular risk factors (cardiovascular disorders, hypertension, hypotension, hypercholesterolemia, dyslipemia, atherosclerosis, diabetes) accumulate in patients with dementia and are at the basis of the pathogenic mechanisms leading to vascular dementia (VD) ([@b42-ndt-3-303]; [@b49-ndt-3-303]; [@b50-ndt-3-303]).

Studies with donepezil ([@b25-ndt-3-303]; [@b244-ndt-3-303]), and other AChEIs ([@b74-ndt-3-303]), have shown modest effects in VD. Improvements have been observed in cognition, behavior, and activities of daily living in VD patients treated with donepezil in a similar fashion to those detected in AD ([@b74-ndt-3-303]; [@b25-ndt-3-303]; [@b100-ndt-3-303]; [@b244-ndt-3-303]; [@b26-ndt-3-303]; [@b75-ndt-3-303]; Roman 2004; [@b193-ndt-3-303]). The combined analysis of 2 identical randomized, double-blind, placebo-controlled, 24-week studies involving 1219 patients enrolled at 109 investigational sites in the USA, Europe, Canada, and Australia, revealed that donepezil groups showed significant improvements in cognition, global function, and ADLs ([@b193-ndt-3-303]). In post-marketing studies, donepezil in VD (sometimes called AD + cerebrovascular disease) patients appears to show similar benefits to those observed in AD patients in the areas of cognition, global function, and quality of life ([@b141-ndt-3-303]; [@b200-ndt-3-303]). The main features of VD patients included in donepezil studies were the following: 68% of patients had a history of at least one stroke, and 28% of patients had a history of transient ischemic attacks before dementia; 99% of cases exhibited cortical and subcortical infarcts; 73% of patients had experienced an abrupt onset of cognitive symptoms; and vascular risk factors were prominent and included hypertension (70%), smoking (62%), and hypercholesterolemia (39%) (Pratt 2005). In general, diagnostic criteria, inclusion criteria, autcome measures (psychometric and instrumental), and follow-up studies are deficient in clinical trials with VD patients; furthermore, many cases with minor cerebrovascular damage and vascular risk factors are currently included in AD trials and neglected in VD trials ([@b49-ndt-3-303], [@b50-ndt-3-303], [@b51-ndt-3-303]).

An important cerebrovascular component is present in most AD cases older than 70--75 years of age, and most cases of dementia are of the mixed type in older patients (\> 80 years) who exhibit a clear brain hypoperfusion pattern as well as accumulation of vascular risk factors ([@b42-ndt-3-303], [@b43-ndt-3-303]; [@b49-ndt-3-303], [@b50-ndt-3-303], [@b51-ndt-3-303]). Glucose metabolism tends to decline over time in the bilateral precuneus and posterior cingulated gyri and in the frontal, temporal and parietal cortices of AD patients ([@b107-ndt-3-303]). Studies of regional cerebral blood flow (rCBF) as assessed by SPECT revealed that AD patients showed a preserved rCBF in the right and left anterior cingulated gyri, right middle temporal gyrus, right inferior parietal lobe, and prefrontal cortex after 1-year of treatment with donenezil ([@b157-ndt-3-303]). Significant rCBF reduction was observed in the temporal lobe and occipital-temporal cortex of the left hemisphere of untreated patients, whereas no significant change was observed in patients treated with donepezil for 1 year ([@b160-ndt-3-303]). In a small study (n = 10), patients with vascular dementia improved their cognitive function and the latency of the P300 auditory ERPs after one month of treatment with donepezil ([@b168-ndt-3-303]). In another study with 15 VD patients, a marginal effect was observed on MMSE scores, with substantial gains on tests of working memory and delayed recognition memory ([@b222-ndt-3-303]). According to some Japanese authors, vascular lesions and related risk factors may influence responsiveness to donepezil in AD. For instance, high HDS-R (Revised-Hasegawa Dementia Scale), low CDT (Clock Drawing Test) scores, low CDR (Clinical Dementia Rating), and the presence of hypertension and periventricular hyperintensities predicted the profile of true responders ([@b87-ndt-3-303]). Others have found that antihypertensive medications in AD patients treated with AChEIs are associated with an independent improvement on cognition after 40 weeks of treatment ([@b194-ndt-3-303]).

Side-effects and major adverse drug reactions (ADRs)
====================================================

On average, side-effects in donepezil trials account for 20%--60% of dropouts and are present in 10%--70% of the patients depending upon type and severity of the ADRs. Side-effects and ADRs associated with donepezil can be classified in two main categories: common side-effects, most of them observed in clinical trials with AD patients, and unfrequent or extraordinary side-effects, seen in especial conditions or in small clusters of patients with different pathologies under treatment with other concomitant drugs. The most frequent ADRs ([Table 3](#t3-ndt-3-303){ref-type="table"}) occurring in more than 5% of patients treated with donepezil include body events (45%), cardiovascular problems (18%), alterations in the digestive system (34%), hematic and lymphatic alterations (5%), metabolic and nutritional changes (6%), musculoskeletal problems (17%), complications in the respiratory system (22%), skin and appendages (14%), special senses (5%), urogenital (24%), and CNS (52%) (agitation, insomnia, confusion, depression, anxiety, dizziness, vertigo, headache, restlessness, hallucinations) ([@b35-ndt-3-303]; [@b188-ndt-3-303]; [@b69-ndt-3-303]; Nordberg and Svensson 1999; [@b243-ndt-3-303]; [@b73-ndt-3-303]; [@b101-ndt-3-303]; [@b191-ndt-3-303]; [@b17-ndt-3-303]; [@b113-ndt-3-303]; [@b63-ndt-3-303]; Johannsen et al 2006). Other important side-effects observed in patients treated with donepezil include agitation, aggressive and violent behavior in AD and Down's syndrome; extrapyramidal symptoms and tardive dyskinesia in schizophrenia and psychotic disorders; catatonia in DLB; and a number of rare effects, such as athetosis, Pisa syndrome (pleurothonus) ([@b131-ndt-3-303]; [@b150-ndt-3-303]), a fulminant chemical hepatitis possibly associated with donepezil and sertraline therapy in an 83-year-old woman ([@b234-ndt-3-303]), purpuric rash in an 82-year-old woman receiving long-term treatment with atenolol and doxazosin ([@b34-ndt-3-303]), hypnopompic hallucinations ([@b254-ndt-3-303]), urinary incontinence ([@b103-ndt-3-303]), extrapyramidal syndrome ([@b139-ndt-3-303]; [@b61-ndt-3-303]), seizures ([@b12-ndt-3-303]), pancreatitis, syncope ([@b101-ndt-3-303]), mania ([@b16-ndt-3-303]; [@b114-ndt-3-303]), violent behavior ([@b33-ndt-3-303]), and some other ADRs in isolated cases with different pathologies ([Table 3](#t3-ndt-3-303){ref-type="table"}).

Donepezil may adversely influence cardiovascular autonomic control ([@b148-ndt-3-303]). More than 40% of elderly subjects susceptible of treatment with AChEIs show some kind of cardiac dysfunction. Donepezil reduces mean heart rate, especially low (0.04--0.15 Hz) and high (0.15--0.40 Hz) frequency components of the ECG (1--30 sec modulation of heart rate variability) ([@b144-ndt-3-303]). In patients receiving donepezil for more than 1 year several cases of syncope have been reported. In 31% of the cases, no cause of syncope was found; and in 69% of the cases the cause of syncope was associated with carotid sinus syndrome, complete atrioventricular block, sinus node dysfunction, severe orthostatic hypotension and paroxysmal atrial fibrillation ([@b28-ndt-3-303]).

Another important issue in the prescription of AChEIs is the potential interaction of these agents with psychotropic drugs and other medications. Drug--drug interactions can be observed between donepezil and antidepressants such as serotonin uptake inhibitors (sertraline, paroxetine, fluoxetine) and triclycics (imipramine, maprotiline), or with antipsychotics (risperidone, olanzapine, quetiapine), antihistaminics, and anti-epileptics. Donepezil can aggravate extrapyramidal symptoms when co-administered with atypical antipsychotics (eg, risperidone). The cholinergic activity of some histamine H1 receptor antagonists or tricyclic antidepressants can be antagonized by donepezil. Despite all these theoretical possibilities, most studies reported to date demonstrate that drug--drug interactions with donepezil (memantine, risperidone, sertraline, levodopa, thioridazine, theophylline, furosemide, cimetidine, warfarin, digoxin, ginkgo biloba, piracetam, CDP-choline, anapsos, topiramate) do not show clinical relevance ([@b223-ndt-3-303], [@b224-ndt-3-303], [@b225-ndt-3-303], [@b226-ndt-3-303]; [@b253-ndt-3-303]; [@b156-ndt-3-303]; [@b167-ndt-3-303]; [@b172-ndt-3-303]; [@b181-ndt-3-303]; [@b184-ndt-3-303]; [@b202-ndt-3-303]; [@b240-ndt-3-303]), except in isolated cases ([@b139-ndt-3-303]; [@b257-ndt-3-303]). The concurrent administration of ketoconazole and donepezil produces no change in ketoconazole plasma concentrations, but a statistically significant change in donepezil plasma concentrations. These changes might be associated with CYP2D6-related enzyme interactions ([@b227-ndt-3-303]). A case of malignant-like syndrome due to donepezil and maprotiline has been reported ([@b165-ndt-3-303]). Another case of malignant syndrome has been reported in a 68-year-old Japanse patient with history of delusions and hallucination under treatment with bromperidol (12 mg) and donepezil (5 mg) ([@b232-ndt-3-303]). Donepezil may also interact with some anesthetics. It can not be excluded that donepezil act on muscle plaque, blocking acetylcholine hydrolysis and antagonizing atracurium, since in a 75-year-old AD patient undergoing left colectomy under general anesthesia, after 14 months of treatment with donepezil, succinylcholine-induced relaxation was markedly prolonged and the effect of atracurium besylate was inadequate even at very high doses ([@b197-ndt-3-303]). Suxamethonium and donepezil may also be a cause of prolonged paralysis ([@b64-ndt-3-303]).

Recent findings indicate that donepezil users may experience changes in lipid profile. Statistically significant higher levels of triglycerides, cholesterol, LDL-cholesterol, and VLDL-cholesterol have been found in donepezil users as compared with non-users ([@b1-ndt-3-303]). Moreover, high cholesterol levels correlated with faster decline at 1-year follow-up in AD patients on AChEI therapy ([@b31-ndt-3-303]). In this regard, it is important to keep in mind that alterations in lipid metabolism might represent an additional risk factor for dementia and that APOE-related cholesterol changes are currently seen in AD ([@b42-ndt-3-303], [@b43-ndt-3-303]; [@b50-ndt-3-303], [@b51-ndt-3-303]). If donepezil-related cholesterol alterations are confirmed in well-controlled trials, in which genotype-related patient stratification is highly recommended, then donepezil should be avoided in vulnerable cases.

Pharmacogenetics
================

With the advent of recent knowledge on the human genome ([@b111-ndt-3-303]) and the identification and characterization of AD-related genes ([@b52-ndt-3-303]), as well as novel data regarding CYP family genes and other genes whose enzymatic products are responsible for drug metabolism in the liver (eg, NATs, ABCBs/MDRs, TPMT), it has been convincingly postulated that the incorporation of pharmacogenetic and pharmacogenomic procedures in drug development might bring about substantial benefits in terms of therapeutics optimization in dementia ([@b40-ndt-3-303], [@b41-ndt-3-303]; [@b44-ndt-3-303], [@b45-ndt-3-303]) and in many other complex disorders, assuming that genetic factors are determinant for both premature neuronal death in AD and drug metabolism ([@b44-ndt-3-303], [@b45-ndt-3-303]; [@b52-ndt-3-303]). With pharmacogenetics we can understand how genomic factors associated with genes encoding enzymes responsible for drug metabolism regulate pharmacokinetics and pharmacodynamics (mostly safety issues) ([@b76-ndt-3-303]; [@b236-ndt-3-303]; [@b237-ndt-3-303]). With pharmacogenomics we can differentiate the specific disease-modifying effects of drugs (efficacy issues) acting on pathogenic mechanisms directly linked to genes whose mutations determine alterations in protein synthesis or subsequent protein misfolding and aggregation ([@b40-ndt-3-303], [@b41-ndt-3-303]; [@b158-ndt-3-303]; [@b42-ndt-3-303]; [@b44-ndt-3-303], [@b45-ndt-3-303]). The capacity of drugs to reverse the effects of the activation of pathogenic cascades (phenotype expression) regulated by networking genes basically deals with efficacy issues. The application of these procedures to dementia is a very difficult task, since dementia is a complex disorder in which more than 200 genes might be involved ([@b52-ndt-3-303]). In addition, it is very unlikely that a single drug be able to reverse the multifactorial mechanisms associated with premature neuronal death in most dementing processes with a complex phenotype represented by memory decline, behavioral changes, and progressive functional deterioration. This clinical picture usually requires the utilization of different drugs administered simultaneously, including memory enhancers, psychotropics (antidepressants, neuroleptics, anxiolytics), anticonvulsants, antiparkinsonians, and also other types of drugs of current use in the elderly due to the presence of concomitant ailments (eg, hypertension, cardiovascular disorders, diabetes, hypercholesterolemia).

Although drug effect is a complex phenotype that depends on many factors, it is estimated that genetics accounts for 20%--95% of variability in drug disposition and pharmacodynamics ([@b236-ndt-3-303]). Cholinesterase inhibitors of current use in AD, such as donepezil and rivastigmine (and tacrine, as well) are metabolized via CYP-related enzymes ([Table 1](#t1-ndt-3-303){ref-type="table"}). These drugs can interact with many other drugs which are substrates, inhibitors or inducers of the cytochrome P-450 system, this interaction eliciting liver toxicity and other adverse drug reactions (ADRs) ([@b44-ndt-3-303], [@b45-ndt-3-303]) ([Tables 1](#t1-ndt-3-303){ref-type="table"} and [3](#t3-ndt-3-303){ref-type="table"}). Many of these substances are metabolized by enzymes known to be genetically variable, including: (a) esterases: butyrylcholinesterase, paraoxonase/arylesterase; (b) transferases: N-acetyltransferase, sulfotransferase, thiol methyltransferase, thiopurine methyltransferase, catechol-O-methyltransferase, glutathione-S-transferases, UDP-glucuronosyltransferases, glucosyltransferase, histamine methyl-transferase; (c) reductases: NADPH:quinine oxidoreductase, glucose-6-phosphate dehydrogenase; (d) oxidases: alcohol dehydrogenase, aldehydehydrogenase, monoamine oxidase B, catalase, superoxide dismutase, trimethylamine N-oxidase, dihydropyrimidine dehydrogenase; and (e) cytochrome P450 enzymes, such as CYP1A1, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A5, and many others ([@b121-ndt-3-303]). Polymorphic variants in these genes can induce changes in drug metabolism altering the efficacy and safety of the prescribed drugs. Drug metabolism includes phase I reactions (ie, oxidation, reduction, hydrolysis) and phase II conjugation reactions (ie, acetylation, glucuronidation, sulfation, methylation). The typical paradigm for the pharmacogenetics of phase I drug metabolism is represented by the cytochrome P450 enzymes, a superfamily of microsomal drug-metabolizing enzymes. P450 enzymes represent a superfamily of hemethiolate proteins widely distributed in bacteria, fungi, plants and animals. The P450 enzymes are encoded in genes of the CYP superfamily and act as terminal oxidases in multicomponent electron transfer chains which are called P450-containing monooxigenase systems. Some of the enzymatic products of the CYP gene superfamily can share substrates, inhibitors and inducers whereas others are quite specific for their substrates and interacting drugs ([@b158-ndt-3-303]; [@b76-ndt-3-303]).

The principal enzymes with polymorphic variants involved in phase I reactions are the following: CYP3A4/5/7, CYP2E1, CYP2D6, CYP2C19, CYP2C9, CYP2C8, CYP2B6, CYP2A6, CYP1B1, CYP1A1/2, epoxide hydrolase, esterases, NQO1 (NADPH-quinone oxidoreductase), DPD (dihydropyrimidine dehydrogenase), ADH (alcohol dehydrogenase), and ALDH (aldehyde dehydrogenase). The microsomal, membrane-associated, P450 isoforms CYP3A4, CYP2D6, CYP2C9, CYP2C19, CYP2E1, and CYP1A2 are responsible for the oxidative metabolism of more than 90% of marketed drugs; and CYP3A4 metabolizes more drug molecules than all other isoforms together. Major enzymes involved in phase II reactions include the following: UGTs (uridine 5′-triphosphate glucuronosyl transferases), TPMT (thiopurine methyl-transferase), COMT (catechol-O-methyltransferase), HMT (histamine methyl-transferase), STs (sulfotransferases), GST-A (glutathion S-transferase A), GST-P, GST-T, GST-M, NAT2 (N-acetyl transferase), NAT1, and others ([@b121-ndt-3-303]). Most of these polymorphic genes exhibit geographic and ethnic differences. These differences influence drug metabolism in different ethnic groups in which drug dosage should be adjusted according to their enzymatic capacity, differentiating normal or extensive metabolizers (EMs), poor metabolizers (PMs) and ultrarapid metabolizers (UMs) ([@b44-ndt-3-303], [@b45-ndt-3-303]).

It is very well known for many years the heterogeneity of AD and how apparently identical phenotypes assessed with international clinical criteria (NINCDS-ADRDA, DSM-IV, ICD-10) do not always respond to the same drugs ([@b47-ndt-3-303], [@b48-ndt-3-303]; [@b44-ndt-3-303], [@b45-ndt-3-303]). This may be due to different factors, including pharmacokinetic and pharmacodynamic properties of drugs, nutrition, liver function, concomitant medications, and individual genetic factors ([@b45-ndt-3-303]). In fact, the therapeutic response of AD patients to conventional cholinesterase inhibitors is partially effective in only 10%--20% of the cases, with side-effects, intolerance, and non-compliance in more than 60% of the patients due to different reasons (eg, efficacy, safety) ([@b94-ndt-3-303], [@b95-ndt-3-303]; [@b48-ndt-3-303]). Therefore, the individualization of therapy or pharmacological tailorization in AD and other CNS disorders is just a step forward of the longstanding goal of molecular pharmacogenomics taking advantage from the information and procedures provided by the sequencing of the entire human genome ([@b111-ndt-3-303]).

Several studies indicate that the presence of the APOE-4 allele differentially affects the quality and size of drug responsiveness in AD patients treated with cholinergic enhancers (tacrine, donepezil, rivastigmine) ([@b176-ndt-3-303]; [@b177-ndt-3-303]; Almqvist et al 2001). For example, APOE-4 carriers show a less significant therapeutic response to tacrine (60%) than patients with no APOE-4 ([@b177-ndt-3-303]). In another study the frequency of APOE-4 alleles was higher in responders to a single oral dose of tacrine (Almqvist et al 2001). More than 80% of APOE-4(−) AD patients showed marked improvement after 30 weeks of treatment with tacrine, whereas 60% of APOE-4(+) carriers had a poor response ([@b177-ndt-3-303]). Others found no differences after 6 months of treatment with tacrine among APOE genotypes, but after 12 months the CIBIC scores revealed that APOE-4 carriers had declined more than the APOE-2 and APOE-3 patients, suggesting that a faster rate of decline was evident in the APOE-4 patients probably reflecting that APOE-4 inheritance is a negative predictor of treatment of tacrine in AD ([@b207-ndt-3-303]). It has also been shown that the APOE genotype may influence the biological effect of donepezil on APP metabolism in AD ([@b30-ndt-3-303]). Prospective studies with galantamine in large samples of patients in Europe ([@b2-ndt-3-303]) and in USA ([@b180-ndt-3-303]) showed no effect of APOE genotypes on drug efficacy, but a retrospective study with a small number of AD cases in Croatia showed the intriguing result of 71% responders to galantamine treatment among APOE-4 homozygotes ([@b11-ndt-3-303]). [@b138-ndt-3-303] reported that gender is likely to be a more powerful determinant of outcome of anticholinesterase treatment than APOE status in the short term. In contrast, other studies do not support the hypothesis that APOE and gender are predictors of the therapeutic response of AD patients to tacrine or donepezil ([@b185-ndt-3-303]). In a recent study, [@b175-ndt-3-303] showed that APOE-4 carriers exhibited a better response to donepezil. Similar results have been found by Bizzarro et al (2006); however, [@b185-ndt-3-303] did not find any significant difference between APOE-4-related responders and non-responders to donepezil. An APOE-related differential response has also been observed in patients treated with other compounds devoid of acetylcholinesterase inhibiting activity (CDP-choline, anapsos) ([@b6-ndt-3-303]; [@b7-ndt-3-303]) suggesting that APOE-associated factors may influence drug activity in the brain either directly acting on neural mechanisms or indirectly influencing diverse metabolic pathways. To date, few studies have addressed in a prospective manner the impact of pharmacogenetic and pharmacogenomic factors on AD therapeutics; however, recent data indicate that the therapeutic response in AD is genotype-specific ([@b47-ndt-3-303], [@b48-ndt-3-303]; [@b40-ndt-3-303], [@b41-ndt-3-303]; [@b42-ndt-3-303]; [@b51-ndt-3-303]; [@b44-ndt-3-303], [@b45-ndt-3-303]).

CYP2D6-related therapeutic response
-----------------------------------

The CYP2D6 enzyme, encoded by a gene that maps on 22q13.1--13.2, catalyzes the oxidative metabolism of more than 100 clinically important and commonly prescribed drugs such as cholinesterase inhibitors (tacrine, donepezil, galantamine), antidepressants, neuroleptics, opioids, some β-blockers, class I antiarrhythmics, analgesics and many other drug categories, acting as substrates, inhibitors or inducers with which cholinesterase inhibitors may potentially interact, this leading to the outcome of ADRs ([@b44-ndt-3-303], [@b45-ndt-3-303]). The CYP2D6 locus is highly polymorphic, with more than 100 different CYP2D6 alleles identified in the general population showing deficient (poor metabolizers, PM), normal (extensive metabolizers, EM) or increased enzymatic activity (ultra-rapid metabolizers, UM). Most individuals (\> 80%) are EMs; however, remarkable interethnic differences exist in the frequency of the PM and UM phenotypes among different societies all over the world ([@b112-ndt-3-303]; [@b58-ndt-3-303]). On the average, approximately 6.28% of the world population belongs to the PM category. Europeans (7.86%), Polynesians (7.27%), and Africans (6.73%) exhibit the highest rate of PMs, whereas Orientals (0.94%) show the lowest rate. The frequency of PMs among Middle Eastern populations, Asians, and Americans is in the range of 2%--3% ([@b112-ndt-3-303]; [@b44-ndt-3-303], [@b45-ndt-3-303]; [@b58-ndt-3-303]).

The most frequent CYP2D6 alleles in the European population are the following: CYP2D6\*1 (wild-type) (normal), CYP2D6\*2 (2850C\>T) (normal), CYP2D6\*3 (2549A\>del) (inactive), CYP2D6\*4 (1846G\>A) (inactive), CYP2D6\*5 (gene deletion) (inactive), CYP2D6\*6 (1707T\>del) (inactive), CYP2D6\*7 (2935A\>C) (inactive), CYP2D6\*8 (1758G\>T) (inactive), CYP2D6\*9 (2613--2615 delAGA) (partially active), CYP2D6\*10 (100C\>T) (partially active), CYP2D6\*11 (883G\>C) (inactive), CYP2D6\*12 (124G\>A) (inactive), CYP2D6\*17 (1023C\>T) (partially active), and CYP2D6 gene duplications (with increased or decreased enzymatic activity depending upon the genes involved) ([@b46-ndt-3-303]).

EMs are more prevalent in AD (\*1/\*1, 49.42%; \*1/\*10, 8.04%) (total AD-EMs: 57.47%) than in controls (\*1/\*1, 44.12%; \*1/\*10, 0%) (total C-EMs: 44.12%). In contrast, IMs are more frequent in controls (41.18%) than in AD (25.29%), especially the \*1/\*4 (C: 23.53%; AD: 12.64%) and \*4/\*10 genotypes (C: 5.88%; AD: 1.15%). The frequency of PMs was similar in AD (9.20%) and controls (8.82%), and UMs were more frequent among AD cases (8.04%) than in controls (5.88%) ([@b46-ndt-3-303]).

The genetic variation between AD and controls associated with CYP2D6 genotypes is 13.35% in EMs, 15.89% in IMs, 0.38% in PMs, and 2.16% in UMs, with an absolute genetic variation of 31.78% between both groups, suggesting that this genetic difference might influence AD pathogenesis and therapeutics ([@b46-ndt-3-303]).

In the first CYP2D6-related pharmacogenetic study with a combination therapy (donepezil + CDP-choline + piracetam + nicergoline) in AD, EMs improved their cognitive function (MMSE score) from 21.58 ± 9.02 at baseline to 23.78 ± 5.81 after 1-year treatment (r = +0.82; a Coef. = +20.68; b Coef.: +0.4). IMs also improved from 21.40 ± 6.28 to 22.50 ± 5.07 (r = +0.96; a Coef. = +21.2; b Coef. = +0.25), whereas PMs and UMs deteriorate from 20.74 ± 6.72 to 18.07 ± 5.52 (r = −0.97; a Coef. = +21.63; b Coef. = −0.59), and from 22.65 ± 6.76 to 21.28 ± 7.75 (r = −0.92; a Coef. = +23.35; b Coef. = −0.36), respectively. According to these results, PMs and UMs were the worst responders, showing a progressive cognitive decline with no therapeutic effect, and EMs and IMs were the best responders, with a clear improvement in cognition after 1 year of treatment ([Figures 1](#f1-ndt-3-303){ref-type="fig"}, [2](#f2-ndt-3-303){ref-type="fig"}). Among EMs, AD patients harbouring the \*1/\*10 genotype (r = +0.97; a Coef. = +19.27; b Coef. = +0.55) responded better than patients with the \*1/\*1 genotype (r = +0.44; a Coef.= +22.10; b Coef. = +0.25). The best responders among IMs were the \*1/\*3 (r = +0.98; a Coef. = +20.65; b Coef. = 1.18), \*1/\*6 (r = 0.93; a Coef. = +22.17; b Coef. = +0.44) and \*1/\*5 genotypes (r = +0.70; a Coef. = +19.96; b Coef. = +0.25), whereas the \*1/\*4, \*10/\*10, and \*4/\*10 genotypes were poor responders. Among PMs and UMs, the poorest responders were carriers of the \*4/\*4 (r = −0.98; a Coef. = +19.72; b Coef. = −0.91) and \*1xN/\*1 genotypes (r = −0.97; a Coef. = +24.55; b Coef. = −0.98), respectively ([Figure 3](#f3-ndt-3-303){ref-type="fig"}). The CYP2D6-related therapeutic responses can be modified by the presence of the APOE-4/4 genotype which converts EMs and IMs in poor responders ([@b46-ndt-3-303]).

From this study, we can conclude the following: (1) there is an accumulation of AD-related genes of risk in PMs and UMs; (2) PMs and UMs tend to show higher transaminase activities than EMs and IMs; (3) EMs and IMs are the best responders, and PMs and UMs are the worst responders to a combination therapy with cholinesterase inhibitors, neuroprotectants, and vasoactive substances ([Figures 1](#f1-ndt-3-303){ref-type="fig"}, [2](#f2-ndt-3-303){ref-type="fig"}, [3](#f3-ndt-3-303){ref-type="fig"}); (4) EMs and IMs can be converted into poor responders by the presence of the APOE-4/4 genotype; and (5) the pharmacogenetic response in AD appears to be dependent upon the networking activity of genes involved in drug metabolism and genes involved in AD pathogenesis ([@b46-ndt-3-303]).

Taking into consideration the available data, it might be inferred that at least 15% of the AD population may exhibit an abnormal metabolism of cholinesterase inhibitors and/or other drugs which undergo oxidation via CYP2D6-related enzymes. Approximately 50% of this population cluster would show an ultrarapid metabolism, requiring higher doses of cholinesterase inhibitors to reach a therapeutic threshold, whereas the other 50% of the cluster would exhibit a poor metabolism, displaying potential adverse events at low doses. If we take into account that approximately 60%--70% of therapeutic outcomes depend upon pharmacogenomic criteria (eg, pathogenic mechanisms associated with AD-related genes), it can be postulated that pharmacogenetic and pharmacogenomic factors are responsible for 75%--85% of the therapeutic response (efficacy) in AD patients treated with conventional drugs ([@b47-ndt-3-303], [@b48-ndt-3-303]; [@b40-ndt-3-303], [@b41-ndt-3-303]; [@b42-ndt-3-303]; [@b53-ndt-3-303]; [@b44-ndt-3-303], [@b45-ndt-3-303]; [@b58-ndt-3-303]; [@b46-ndt-3-303]). Of particular interest are the potential interactions of cholinesterase inhibitors with other drugs of current use in patients with AD, such as antidepressants, neuroleptics, antiarrhythmics, analgesics, and antiemetics which are metabolized by the cytochrome P450 CYP2D6 enzyme ([@b19-ndt-3-303]). Although most studies predict the safety of donepezil and galantamine, as the two principal cholinesterase inhibitors metabolized by CYP2D6-related enzymes, no pharmacogenetic studies have been performed so far on an individual basis to personalize the treatment, and most studies reporting safety issues are the result of pooling together pharmacological and clinical information obtained with conventional procedures. In certain cases, genetic polymorphism in the expression of CYP2D6 is not expected to affect the pharmacodynamics of some cholinesterase inhibitors because major metabolic pathways are glucuronidation, O-demethylation, N-demethylation, N-oxidation, and epimerization. However, excretion rates are substantially different in EMs and PMs. For instance, in EMs, urinary metabolites resulting from O-demethylation of galantamine represent 33.2% of the dose compared with 5.2% in PMs, which show correspondingly higher urinary excretion of unchanged galantamine and its N-oxide ([@b142-ndt-3-303]). Therefore, still there are many unanswered questions regarding the metabolism of cholinesterase inhibitors and their interaction with other drugs (potentially leading to ADRs) which require pharmacogenetic elucidation.

Conclusions
===========

Donepezil is a piperidine-derivative reversible AChEI that enhances cholinergic neurotransmission and may have other non-cholinergic actions with potential benefit for dementia ([Table 2](#t2-ndt-3-303){ref-type="table"}). Main pharmacological properties of donepezil include the following ([Tables 1](#t1-ndt-3-303){ref-type="table"}): (1) after oral ingestion, peak plasma concentrations are achieved in 3--5 hours; (2) absortion is not affected by food; (3) linear pharmacokinetics over a dose range of 1--10 mg/day; (4) steady-state plasma concentration reached in 14--21 days with daily dosing; (5) mean steady-state plasma concentrations are dose proportional; (6) mean cerebral spinal fluid/plasma concentration is 0.157; (7) 96% of circulating donepezil is protein bound; (8) elimination half-life is approximately 70 hours; (9) it is mostly excreted unchanged in urine; (10) there is some CYP3A4- and CYP2D6-related metabolism; (11) there are not significant drug interactions; (12) the most important ADRs associated with donepezil are body events (45%), cardiovascular (18%), digestive (34%), hematic and lymphatic (5%), metabolic and nutritional (6%), musculoskeletal (17%), nervous system (52%), respiratory system (22%), skin and appendages (14%), special senses (5%), urogenital (25%), and some other rare side effects (1%--2%) ([Table 3](#t3-ndt-3-303){ref-type="table"}); (12) donepezil is effective in mAD and sAD cases as well as in patients with VD, showing a modest improvement in cognition, behavior, and function ([Table 2](#t2-ndt-3-303){ref-type="table"}); and (13) the effects of donepezil are dose-dependent, with optimal effects in the range of 5--10 mg/day.

After 20 years of experience in AD therapeutics, we can conclude that the main causes of therapeutic failure with AChEIs in general and donepezil in particular in AD are the following: (1) the central cholinergic deficit in AD is not the cause of the disease but the consequence of neurodegeneration associated with complex pathogenic mechanisms involving many different genomic, proteomic, and metabolomic cascades; (2) pharmacokinetic and pharmacodynamic weaknesses of the AChEIs; (3) an out-of-date screening protocol (outcome measures) to evaluate drug efficacy only relying on psychometric parameters, neglecting the fundamental utility of biological markers and/or predictors of neuroprotection in the long-term; (4) critical problems of patient recruitment not differentiating pure AD cases from cases of AD with cerebrovascular component and/or other medical conditions; (5) differences in the genetic profile of AD patients who exhibit a genotype-related therapeutic response (pharmacogenomics; efficacy issues); and (6) pharmacogenetic problems associated with genes responsible for the metabolism of drugs (pharmacogenetics; safety issues).

Despite all these considerations, AChEIs may be of some utility in 20%--30% of AD patients, and in this selected cluster of moderate responders the AChEIs should be used until other better therapeutic alternatives are available. The potential efficacy of donepezil in responders may be due to an adequate pharmacogenetic-pharmacogenomic profile associated with cholinesterase inhibition and/or other mechanisms of action directly or indirectly linked to cholinergic regulation (ie, anti-oxidation, inhibition of neuronal excitotocity-related mechanisms, cerebrovascular regulation).

Some other conclusions can also be drawn, such as that: (a) AChEIs (and most anti-dementia drugs) do not appear to be cost-effective; (b) novelty criteria and marketing pressure are not good advisers for treatment shift from a drug to another (there is no clear evidence that one AChEI is better than another, but some AChEIs are more harmful than others); (c) some pharmacological properties of donepezil might be beneficial in other forms of dementia and also in some other CNS disorders; (d) multifactorial interventions with combination therapy (including donepezil in the cocktail) may be more effective in AD than monotherapies; (e) in any circumstance, the therapeutic response in AD depends largely on the genomic profile of the patients; (f) cholinesterase inhibitors should be avoided in those AD patients in whom their genomic profile predict a poor therapeutic outcome; and (g) pharmacogenetics and pharmacogenomics studies can contribute to optimize therapeutics in the coming future by improving efficacy and safety and reducing costs.

![CYP2D6-related therapeutic response in Alzheimer's disease. Cognitive performance in extensive (EM), intermediate (IM), poor (PM), and ultra-rapid metabolizers (UM) during treatment with a multifactorial (combination) therapy.\
**Notes and abbreviations:** MMSE, Mini-Mental State Examination; 0, Baseline Score (prior to treatment); 1--12, 1--12 months of treatment; SD, standard deviation; X, mean (MMSE score).](ndt-3-303f1){#f1-ndt-3-303}

![CYP2D6-related cognitive performance in Alzheimer's disease. Correlation analysis among CYP2D6-related extensive (EM), intermediate (IM), poor (PM), and ultra-rapid metabolizers (UM) to characterize responders and non-responders during 1-year treatment period with a multifactorial therapy.](ndt-3-303f2){#f2-ndt-3-303}

###### 

CYP2D6-related therapeutic response in Alzheimer's disease. Influence of CYP2D6 genotypes on cognitive performance during treatment with a multifactorial therapy (CDP-choline, 500 mg/day; piracetam, 1600 mg/day; nicergoline, 5 mg/day; donepezil, 5 mg/day).

\(a\) Extensive Metabolizers (EM); (b) Intermediate Metabolizers (IM); Poor Metabolizers (PM); (d) Ultra-rapid Metabolizers (UM).
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###### 

Pharmacological properties of selected acetylcholinesterase inhibitors for the treatment of Alzheimer's disease

  -------------------------------------------------------------------------------------------------------------------------------------------------------------
  Properties                              Tacrine                     Donepezil                   Rivastigmine                         Galantamine
  --------------------------------------- --------------------------- --------------------------- ------------------------------------ ------------------------
  Class                                   Aminoacridine               Piperidine                  Carbamate                            Tertiary alkaloid

  AChE inhibition                         Reversible Noncompetitive   Reversible Noncompetitive   Pseudo-irreversible Noncompetitive   Reversible Competitive

  Dose (mg/day)                           80--160                     5--10                       6--12                                16--24

  Duration                                Short-acting                Short-acting                Intermediate-acting                  Short-acting

  Brain AChE selectivity IC50 (nmol/L)    125                         33                          42,000                               3,900

  Serum BuChE selectivity IC50 (nmol/L)   7.2                         988                         54,000                               18,600

  BuChE/AChE selectivity                  0.06                        30                          1.3                                  4.8

  Cmax (μg/L)                             5.1 (10 mg)\                7.2 (5 mg)\                 5.07 (2 mg × 2)\                     42 (12 mg × 2)\
                                          20.7 (20 mg)\               25.6 (10 mg)                14.1 (6 mg × 2)                      137 (16 mg × 2)
                                          33.9 (30 mg)                                                                                 

  Tmax (h)                                1--2                        3--5                        0.5--2                               0.9--2

  AUC (μg/L/h)                            2--4                        539                         15.4 (3 mg × 2)\                     1.1
                                                                                                  55.9 (6 mg × 2)                      

  T1/2 (h)                                1.3                         50--80                      0.6--2                               7--8

  Bioavailability (%)                     17--37                      100                         35--40                               100

  Protein binding (%)                     55                          96                          40                                   18

  Clearance (L/h/kg)                      2.42                        0.13                        1.5 (6 mg bid)                       0.34

  Vd (L/kg)                               3.5--7                      14                          1.8--2.7                             2.64

  Cytochrome P450                         CYP1A2                      CYP2D6                      Carbomoylation                       CYP2D6

  Metabolism                              CYP2D6                      CYP3A4                                                           CYP3A4

  Active metabolites                      1-hydroxy-tacrine           6-O-desmethyldonepezil      NAP 226--90                          Sanguinine

  Urine excretion (%)                     \<3                         17                          Metabolite                           50

  Efficacy                                4.0--5.3 vs 0.8--2.8        2.8--4.6 vs 0.7--1.2        1.9--4.9 vs 0.7--1.2                 3.1--3.9 vs 1.73

  ADAS-Cog vs Placebo                                                                                                                  

  Adverse effects                                                                                                                      

  Nausea                                  3+                          3+                          3+                                   2+

  Vomiting                                2+                          2+                          2+                                   2+

  Diarrhea                                2+                          2+                          2+                                   1+

  Dizziness                               2+                          1+                          2+                                   1+

  Headache                                1+                          0                           1+                                   0

  Abdominal pain                          1+                          0                           1+                                   0

  Anorexia                                2+                          1+                          1+                                   0

  Bradycardia                             0                           0                           0                                    0

  Fatigue                                 0                           1+                          1+                                   1+

  Muscle clamps                           0                           1+                          0                                    0

  Agitation                               2+                          1+                          0                                    1+

  Dyscrasia                               0                           0                           0                                    0

  Liver dysfunction                       3+                          0                           0                                    0
  -------------------------------------------------------------------------------------------------------------------------------------------------------------

**Sources:** Cacabelos, CIBE Database, 2005; [@b44-ndt-3-303], [@b45-ndt-3-303]; [@b17-ndt-3-303]; [@b94-ndt-3-303], [@b95-ndt-3-303].

###### 

Selected studies with donepezil in Alzheimer's disease and vascular dementia

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                     Year                Disease          N       Study                                              Effect                    Outcome measures                                                                                                Comments
  -------------------------- ------------------- ---------------- ------- -------------------------------------------------- ------------------------- --------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------
  Rogers et al               [@b189-ndt-3-303]   mAD              161     Double-blind\                                      Positive (12 w)           ADAS-Cog; CGIC; MMSE; ADL                                                                                       First reported study; 12% Dropout; No changes in ADL
                                                                          Placebo-controlled                                                                                                                                                                           

  Rogers et al               [@b190-ndt-3-303]   mAD              468     Double-blind\                                      Positive (15 w)           ADAS-Cog; CDR-SB; CIBIC+; MMSE; QoL                                                                             35% Responders; 12% Dropout; No changes in QoL
                                                                          Placebo-controlled                                                                                                                                                                           

  Rogers et al               [@b192-ndt-3-303]   mAD              473     Double-blind                                       Positive (24 w)\          ADAS-Cog; CDR-SB; CIBIC+; MMSE; QoL                                                                             25% Responders; 22% Dropout; No changes in QoL
                                                                                                                             Placebo-controlled                                                                                                                        

  Burns et al                [@b39-ndt-3-303]    mAD              818     Double-blind\                                      Positive (24 w)           ADAS-Cog; CDR-SB; CIBIC+; IDDD; QoL                                                                             23% Dropout; No changes in QoL
                                                                          Placebo-controlled                                                                                                                                                                           

  Rogers et al               [@b191-ndt-3-303]   mAD              133     Double-blind\                                      Positive (254 w)          ADAS-Cog; CDR-SB                                                                                                Safety
                                                                          Placebo-controlled                                                                                                                                                                           

  Matthews et al             [@b146-ndt-3-303]   mAD              80      Open-label                                         Positive (18 m)           ADAS-Cog; MMSE; NPI                                                                                             Cognitive and behavioral improvements in 39% and 37% of patients, respectively

  Rogers                     [@b191-ndt-3-303]   mAD                      Open-label                                         Positive (2 y)            ADAS-Cog                                                                                                        

  Greenberg et al            [@b101-ndt-3-303]   mAD              60      Double-blind\                                      Positive (6 w)            ADAS-Cog                                                                                                        Modest improvement
                                                                          Placebo- controlled\                                                                                                                                                                         
                                                                          Crossover                                                                                                                                                                                    

  Homma et al                [@b110-ndt-3-303]   mAD              263     Double-blind\                                      Positive (24 w)           ADAS-Jcog; CDR-SB; CMCS; J-CGIC; MENFIS                                                                         28% Responders; 14% Dropout; 10% AEs
                                                                          Placebo-controlled                                                                                                                                                                           

  Winblad et al              [@b248-ndt-3-303]   mAD              286     Double-blind\                                      Positive (52 w)           ADL; GBS; GDS; MMSE; NPI                                                                                        33% Dropout; Modest improvement
                                                                          Placebo-controlled                                                                                                                                                                           

  Mohs et al                 [@b152-ndt-3-303]   mAD              431     Double-blind\                                      Positive (52 w)           ADFACS; CDR-SB; MMSE                                                                                            74% Dropout; 51% Responders\
                                                                          Placebo-controlled                                                                                                                                                                           38% reduction in the risk of functional decline vs placebo

  Feldman et al              [@b79-ndt-3-303]    sAD              290     Double-blind\                                      Positive (24 w)           CIBIC+; DAD; FRS; MMSE; NPI; SIB; CGIC                                                                          Modest improvement; 16% Dropout; 83% AEs
                                                                          Placebo-controlled                                                                                                                                                                           

  Tariot et al               [@b220-ndt-3-303]   m/sA\            208     Double-blind\                                      Neutral (24 w)            MMSE; NPI-NH; CDR-SB; PSMS                                                                                      82% completed the study; 97% AEs; concomitant medications; comorbidity; institutionalized patients; cognitive stabilization
                                                 DAD+CVD                  Placebo-controlled                                                                                                                                                                           

  Doody et al                [@b72-ndt-3-303]    AD               763     Double-blind\                                      Positive (24 w)           MMSE; ADAS-Cog; CDR-SB                                                                                          Cognitive improvement
                                                                          Placebo-controlled                                                                                                                                                                           

  Doody et al                [@b71-ndt-3-303]    mAD              205     Follow-up                                          Positive (1 y)            MMSE                                                                                                            Slower decline in MMSE scores

  Parnetti et al             [@b171-ndt-3-303]   AD               59      Placebo-conrolled                                  Positive (6 m)            CSF AChE activity, BuChE activity; β-amyloid, tau, phosphrylated tau proteins                                   Decrease in AChE activity, and no changes in other biomarkers

  Paleacu et al              [@b170-ndt-3-303]   mAD              28      Open-label                                         Positive (6 m)            MMSE; NPI                                                                                                       Significant improvement in behavioral symptoms

  Nobili et al               [@b160-ndt-3-303]   mAD              25      Open-label                                         Positive (1 y)            SPECT (brain perfusion)                                                                                         Preserved brain perfusion

  Gauthier et al             [@b90-ndt-3-303]    m/sAD            290     Placebo-controlled\                                Positive (24 w)           NPI                                                                                                             Improvement in behavioral symptoms
                                                                          Randomized                                                                                                                                                                                   

  Gauthier et al             [@b90-ndt-3-303]    mAD              207     Double-blind\                                      Positive (24 w)           CIBIC+                                                                                                          Cognitive and functional improvement; 82% of patients showed adverse events
                                                                          Placebo-controlled                                                                                                                                                                           

  Gauthier et al             [@b91-ndt-3-303]    m/sAD            290     Double-blind\                                      Positive (24 w)           NPI                                                                                                             Behavioral improvement
                                                                          Placebo-controlled                                                                                                                                                                           

  Wilkinson et al            [@b245-ndt-3-303]   mAD              111     Open-label\                                        Positive (12 w)           ADAS-Cog                                                                                                        Similar improvement; less side-effects; Better compliance with donepezil
                                                                          Comparative: vs rivastigmine                                                                                                                                                                 

  Krishnan et al             [@b129-ndt-3-303]   mAD              67      Double-blind\                                      Positive (24 w)           Cognition; MRI                                                                                                  Cognitive improvement and decrease in hipocampal atrophy
                                                                          Placebo-controlled                                                                                                                                                                           

  Kemp et al                 [@b122-ndt-3-303]   mAD              12      Double-blind\                                      Positive (4 m)            ADAS-Cog; SPECT-M1 muscarinic receptor binding                                                                  Cognitive improvement and increase M1 binding
                                                                          Placebo-controlled                                                                                                                                                                           

  Wilcock et al              2003                mAD              182     Rater-blinded\                                     Negative (52 w)           MMSE; BrADL; ADAS-Cog; NPI; SCB                                                                                 Galantamine better than donepezil
                                                                          Comparative                                                                                                                                                                                  

  Black et al                [@b25-ndt-3-303]    VD               603     Placebo-controlled\                                Positive (24 w)           ADAS-Cog; CIBIC-Plus; ADFACS; CDR-SB                                                                            Improvement in cognition, function and ADL
                                                                          Randomized                                                                                                                                                                                   

  Wilkinson et al            [@b244-ndt-3-303]   VD               616     Placebo-controlled\                                Positive (24 w)           ADAS-Cog; CIBIC+                                                                                                Improvement in cognition and global function
                                                                          Randomized                                                                                                                                                                                   

  Feldman et al              [@b80-ndt-3-303]    m/sAD            290     Double-blind\                                      Positive (24 w)           DAD; IADL+; PSMS+                                                                                               Slower cognitive decline and better\
                                                                          Placebo-controlled\                                                                                                                                                                          ADL performance
                                                                          Randomized                                                                                                                                                                                   

  Adunsky et al              [@b1-ndt-3-303]     AD               105     Open-label                                         Negative                  Plasma lipid profile                                                                                            Increased levels of cholesterol, triglycerides, LDL and VLDL in donepezil users

  Salloway et al             [@b195-ndt-3-303]   MCI              270     Double-blind\                                      Neutral (24 w)            NYUPDRT; ADCS CGIC-MCI; ADAS-Cog; PGA                                                                           20% droupou; 88% adverse events (73% placebo)
                                                                          Placebo-controlled                                                                                                                                                                           

  Holmes et al               [@b109-ndt-3-303]   mAD              134     Randomized withdrawal                              Positive (6 w)            NPI                                                                                                             Improvement in neuropsychiatric symptoms

  Tariot et al               [@b221-ndt-3-303]   m/sAD            404     Combination therapy: donepezil + memantine         Positive (6 m)            MMSE; ADCS-ADL; SIB; CIBIC+; NPI; BRSGP                                                                         Improved cognition, ADLs, global function, behavior and care dependence

  Beusterien et al           [@b20-ndt-3-303]    mAD              3864    Retrospective                                      Positive (\>1 yr)         Nursing Home Placement (NHP)                                                                                    4.4% vs 11.0% in controls

  Seltzer et al              [@b203-ndt-3-303]   mAD              96      Double-blind\                                      Positive (24 w)           ADAS-Cog; MMSE; CMBT; CDR-SB; PGAS; AS                                                                          Early-stage AD
                                                                          Placebo-controlled                                                                                                                                                                           

  Courtney et al AD 2000\    2004                mAD              565     Double-blind\                                      Negative (12 w)           Entry to institutional care\                                                                                    Not cost-effective; No effect on institutionalization rate; No effect on progression of disability
  Collaborative Group 2004                                                Double randomization                                                         Progression of disabilityBADLS                                                                                  

  Jones et al                2004                mAD              64      Open-label\                                        Positive (12 w)           ADAS-Cog; MMSE; DAD Satisfaction rate                                                                           Donepezil superior to galantamine
                                                                          Comparatuve: donepezil vs galantamine                                                                                                                                                        

  Finkel et al               [@b84-ndt-3-303]    mAD              120     Placebo-controlled\                                Neutral (12 w)            NPI; CGI; CGI-S                                                                                                 Neutral effect of the combination therapy
                                                                          Randomized                                                                                                                                                                                   

  Thomas et al               [@b222-ndt-3-303]   VD/AD            16/15   Open-label                                         Positive (16 w)           MMSE; working memory tests; delayed recognition memory                                                          Marginal effects on MMSE score\
                                                                                                                                                                                                                                                                       Gains in working memory

  Bartorelli et al           2005                mAD              225     Observational\                                     Positive (3 m)            MMSE; ADL; IADL; CGIC                                                                                           Improvement in cognitive function after switching(\>60% responders)
                                                                          Switching from donapezil to rivastigmine                                                                                                                                                     

  Hashimoto et al            [@b104-ndt-3-303]   mAD              54      Open-label                                         Positive (1 yr)           MRI; Mean annual rate of hippocampal volume loss                                                                Control subjects have never been under AChEI treatment

  Klinger et al              2005                mAD              913     Post-Marketing\                                    Positive (3 m)            MMSE, QoL                                                                                                       Observational PMS study in patients previously treated with memantine or nootropics
                                                                          Surveillance                                                                                                                                                                                 

  Bullock et al              [@b38-ndt-3-303]    m/sAD            994     Double-blind\                                      Neutral                   Cognitive function; activities of daily living; global functioning; behavioral symptoms                         Comparative study: donepezil vs rivastigmine; Better results with rivastigmine in carriers of the wild-type BuChE genotype
                                                                          Comparative                                                                                                                                                                                  

  Bizzarro et al             [@b24-ndt-3-303]    mAD              41      Observational                                      Negative (1 yr)           MMSE; APOE                                                                                                      No cognitive improvement; APOE-related responses

  Roman et al                [@b193-ndt-3-303]   VD               1219    Double-blind\                                      Positive (24 w)           ADAS-Cog; MMSE; CIBIC+; CDR-SB; ADFACS; ADFACS-IADL                                                             Combined analysis of 2 large-scale trials in 109 investigational sites in USA, Europe, Canada, and Australia
                                                                          Placebo-controlled                                                                                                                                                                           

  Petersen et al             [@b175-ndt-3-303]   MCI              769     Double-blind                                       Negative (3 yrs)\         Conversion to AD; cognition; function                                                                           Comparative with vitamin E; Positive results in APOE-4 carriers
                                                                                                                             Positive (1 yr)                                                                                                                           

  Ancoli-Israel et al        [@b8-ndt-3-303]     mAD\             63      Double-blind\                                      Neutral (8 w)             Actigraphy                                                                                                      No effect on sleep; Comparative: donepezil vs galantamine
                                                 Sleep disorder           Placebo-controlled                                                                                                                                                                           

  Feldman et al              [@b82-ndt-3-303]    m/sAD            290     Placebo-controlled\                                Positive                  CIBIC+; MMSE; SIB; NPI; DAD                                                                                     Benefits over placebo on global, cognitive, functional, and behavioral measures
                                                                          Subgroup analysis                                                                                                                                                                            

  Winblad et al              [@b249-ndt-3-303]   sAD              128     Double-blind, parallel-group, Placebo-controlled   Positive (6 m)            Severe Impairment Battery (SIB)\                                                                                Nursing home patients
                                                                                                                                                       Modified Alzheimer's Disease Cooperative Study activities of daily living inventory for sAD (ADCS-ADL-severe)   

  Johannsen et al            2006                mAD              619     Open-label 12--24 w\                               Positive (12--24 w)       ADAS; MMSE; DAD; NPI                                                                                            69% Responders; 31% Non-respond ers; Cognitive and behavioral benefit
                                                                          Double-blind\                                                                                                                                                                                
                                                                          Placebo-controlled\                                                                                                                                                                          
                                                                          Single-blind 12 w                                                                                                                                                                            

  Bullock et al              [@b36-ndt-3-303]    mAD              994     Randomized                                         Partial effects (2 yrs)   SIB; NPI; GDS; MMSE; ADCS-ADL                                                                                   Age-dependent response; BuChE genotype-related response

  Paci et al                 [@b168-ndt-3-303]   VD               10      Open-label                                         Positive (1 m)            Cognition; P300 ERP                                                                                             Improvement in P300 latency

  Winblad et al              [@b250-ndt-3-303]   m/sAD            286     Open-label                                         Positive (3 yrs)          MMSE; GBSS; GDS; NPI                                                                                            Delayed progression of disease; 90% ADRs

  Shimizu et al              [@b205-ndt-3-303]   mAD              51      Open-label                                         Neutral (10--14 m)        MMSE; SPECT (rCBF)                                                                                              Improvement in frontal rCBF

  Touchon et al              [@b229-ndt-3-303]   AD-DLB           94      Retrospective\                                     Negative (2 yrs)          MMSE; SIB; GDS; NPI; ADCS-ADL; ITT-LOCF                                                                         Rivastigmine superior to donepezil in AD with DLB-like symptoms
                                                                          Comparative: donepezil vs rivastigmine                                                                                                                                                       

  Van Dyck et al             2006                m/sAD            404     Combination therapy with memantine                 Neutral (24 w)            ADCS-ADL; SIB; CIBIC+; NPI                                                                                      Imprevement and stabilization of symptoms
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** ADAS-Cog, Alzheimer's Disease Assessment Scale-Cognitive subscale; ADAS-Jcog, Alzheimer's Disease Assessment Scale-Cognitive subscale, Japanese version; ADCS-ADL, Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory; ADCS CGIC-MCI, Alzheimer's Disease Cooperative Study Clinician's Global Impression of Change for MCI; ADFACS, AD Functional Assessment and Change Scale; ADFACS-IADL, Instrumental activities of daily living; ADL, Activities of Daily Living; AS, Apathy Scale; BADLS, Bristol activities of daily living scale; BRSGP, Behavioral Rating Scale for Geriatric Patients; CDR-SB, Clinical Dementia Rating-Sum of the Boxes; CGIC, Clinical Global Impression of Change; CIBIC+, Clinician's Interview-Based Impression of Change Plus Cargiver Input; CMBT, Computerized Memory Battery Test; CMCS, Caregiver-rated Modified Crichton Scale; DAD, Disability Assessment for Dementia; DLB, Dementia with Lewy bodies; FRS: Functional Rating Scale; GBSS, Gottfries-Brane-Steen scale; GDS: Global Deterioration Scale; IDDD, Modified Interview for Deterioration in Daily Living in Dementia; IADL+, modified instrumental activities of daily living scale; ITT-LOCF; Intent-to-treat last observation carried forward; J-CGIC, Japanese version of CGIC; mAD, mild-moderate Alzheimer's disease; CI, mild cognitive impairment; MENFIS, Mental Function Impairment Scale; MMSE, Mini-Mental Status Examination; PI, Neuropsychiatric Inventory; NPI-NH, Neuropsychiatric Inventory-Nursing Home Version; NYUPDRT: New York University Paragraph Delayed Recall test; QoL, Quality of Life; PGAS, Patient Global Assessment Scale; PSMS+, Modified Physical Self Maintenance Scale; PSP, progressive supranuclear palsy; sAD, moderate-severe Alzheimer's disease; SD, senile dementia; SIB, Severe Impairment Battery; VD, vascular dementia.

###### 

Adverse drug reactions reported in clinical trials with donepezil in Alzheimer's disease and other CNS disorders

  ADRs                                  Frequency[a](#tfn3-ndt-3-303){ref-type="table-fn"}   Disease
  ------------------------------------- ---------------------------------------------------- -------------------
  Pain                                  15%                                                  mAD
  Common cold                           9%                                                   mAD
  Headache                              8%                                                   mAD
  Fatigue                               5%                                                   mAD
  Hypertension                          5%                                                   mAD
  Urinary tract infections              7%--17%                                              mAD, sAD
  Abdominal disturbance                 6%                                                   mAD
  Stomach upset                         6%                                                   mAD
  Anorexia                              6%                                                   mAD
  Bloating                              5%                                                   mAD
  Hematic and lymphatic disorders       5%                                                   mAD
  Metabolic and nutritional disorders   6%                                                   mAD
  Musculoskeletal problems              17%--25%                                             mAD, sAD, DS, DLB
  Accidental fall                       11%--13%                                             mAD, sAD
  Anxiety                               6%--7%                                               mAD, sAD
  Agitation                             24%--56%                                             mAD, sAD, DS
  Insomnia                              11%                                                  mAD
  Confusion                             8%                                                   mAD
  Depression                            8%                                                   mAD
  Dizziness                             7%                                                   mAD
  Restlessness                          5%                                                   mAD
  Vertigo                               5%                                                   mAD
  Accidental injury                     6%--11%                                              mAD, sAD
  Gastroenteritis                       6%                                                   sAD
  Weight loss                           15%--20%                                             mAD, sAD
  Diarrhea                              9%                                                   mAD, sAD
  Coughing                              5%                                                   mAD
  Nasal congestion                      5%                                                   mAD
  Pneumonia                             9%--10%                                              sAD
  Cystitis                              6%                                                   sAD
  Nausea                                6%--8%                                               mAD, sAD
  Asthenia                              3%--5%                                               mAD, sAD
  Accidental bone fracture              6%--8%                                               mAD, sAD
  Constipation                          4%                                                   sAD
  Skin problems                         14%                                                  mAD, sAD, DLB
  Hallucinations                        5%--6%                                               mAD, sAD
  Somatosensory alterations             5%                                                   mAD
  Urogenital disturbances               24%                                                  mAD
  Unusual/abnormal dreams/nightmares    10%--34.3%                                           mAD, MCI, MS
  Cardiovascular dysfunction            30%--40%                                             mAD, sAD
  Lipid metabolism alterations          20%--35%                                             mAD
  Syncope                               1%--10%                                              sAD
  Tardive dyskinesia                    1%--4%                                               mAD, SCZ, PSYD
  Catatonia                             \<1%                                                 DLB
  Pisa syndrome                         \<1%                                                 mAD, sAD, PD
  Athetosis                             \<1%                                                 m/sAD
  Parkinsonism                          \<1%                                                 DLB
  Neuroleptic malignant syndrome        \<1%                                                 mAD, SCZ
  Delirium                              1%--2%                                               m/sAD
  Extrapyramidal symptoms               1%--5%                                               PD; SCZ
  Toxic hepatitis                       \<1%                                                 AD
  Dyskinetic disorders                  \<1%                                                 AD
  Syncope                               \<1%                                                 AD
  Pancreatitis                          \<1%                                                 AD
  Seizures                              1%--3%                                               AD
  Purpuric rash                         \<1%                                                 AD
  Prolonged effects of anesthesia       \<1%                                                 AD

Estimated values from clinical trials and clinical observations reported in the international literature (n = 112)

**Abbreviations:** DLB, dementia with Lewy bodies; DS, Down's syndrome; mAD, Mild-moderate Alzheimer's disease; MS, multiple sclerosis; PD, Parkinson's disease; PSYD; psychotic disorders; sAD, moderate--severe Alzheimer's disease; SCZ, schizophrenia.
